lamivudine has been researched along with efavirenz in 398 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (3.77) | 18.2507 |
| 2000's | 148 (37.19) | 29.6817 |
| 2010's | 187 (46.98) | 24.3611 |
| 2020's | 48 (12.06) | 2.80 |
| Authors | Studies |
|---|---|
| Haefeli, WE; Ketabi-Kiyanvash, N; Lindenmaier, H; Theile, D; Weiss, J | 1 |
| Colonno, R; Dicker, I; Fan, L; Gali, V; Higley, H; Krystal, M; Lin, PF; Nowicka-Sans, B; Parkin, N; Tenney, D; Terry, B; Wang, C; Zhang, S | 1 |
| Chen, J; Chen, X; Geleziunas, R; Hesselgesser, J; Jin, H; Jones, GS; Kim, CU; Tsiang, M; Wright, M; Yu, F; Zeynalzadegan, A | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| DiStefano, DJ; Hazuda, DJ; Lai, MT; McKenna, PM; Miller, MD; Munshi, V; Touch, S; Tucker, TJ; Tynebor, RM; Williams, TM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Brown, KW; Ferris, R; Foster, SA; Fujiwara, T; Garvey, EP; Hazen, RJ; Johns, BA; Kawasuji, T; Kawauchi-Miki, S; Kobayashi, M; Miki, S; Sato, A; Seki, T; Suyama-Kagitani, A; Taishi, T; Underwood, MR; Wakasa-Morimoto, C; Yoshinaga, T | 1 |
| Hamburger, M; Hamy, F; Klimkait, T; Louvel, S; Mojarrab, M; Potterat, O; Sanglier, JJ; Vidal, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, FE; Chen, WX; De Clercq, E; He, QQ; Pannecouque, C; Piao, HR; Wu, HQ; Wu, Y; Yan, ZH | 1 |
| Balzarini, J; Chen, F; Chen, W; De Clercq, E; Liu, Y; Meng, G; Pannecouque, C; Zheng, A | 1 |
| Chen, W; De Clercq, E; Liu, X; Liu, Z; Pannecouque, C; Zhan, P | 1 |
| Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yao, J | 1 |
| Balzarini, J; Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Yu, M; Zhan, P | 1 |
| Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Li, X; Liang, X; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Zhan, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, W; Daelemans, D; De Clercq, E; Huang, B; Liu, X; Pannecouque, C; Yang, J; Zhan, P | 1 |
| Daelemans, D; De Clercq, E; Ding, X; Fang, Z; Huang, B; Kang, D; Li, Z; Liu, X; Lu, X; Pannecouque, C; Xu, H; Zhan, P; Zhang, H; Zhou, Z | 1 |
| Cen, S; Fang, XM; Liu, HY; Pang, X; Su, J; Yu, LY; Zhang, DW; Zhang, T; Zhao, JY | 1 |
| Daelemans, D; De Clercq, E; Kang, D; Liu, X; Pannecouque, C; Tian, Y; Wang, Z; Yu, Z; Zhan, P; Zhang, J | 1 |
| Chen, FE; Gu, SX; Liu, GY; Meng, G; Pannecouque, C; Tang, JF; Wu, FS; Xiao, T; Xu, ZQ; Zhu, YY | 1 |
| Cherukupalli, S; De Clercq, E; Feng, D; Fu, Z; Jiang, X; Kang, D; Liu, X; Pannecouque, C; Wang, Z; Zhan, P | 1 |
| De Clercq, E; Huang, B; Jiang, X; Kang, D; Li, J; Liu, X; Olotu, FA; Pannecouque, C; Soliman, MES; Wang, Z; Zhan, P | 1 |
| Chen, FE; De Clercq, E; Jin, X; Pannecouque, C; Piao, HR; Zhuang, C | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Saag, MS; Schooley, RT | 1 |
| Ahmad, M; Brennan, JM; Caliendo, AM; Fiske, WD; Flanigan, TP; Gormley, JM; Tashima, KT | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Farina, D; Johnson, P; Labriola, DF; Manion, DJ; Morales-Ramirez, J; Rachlis, A; Ruiz, NM; Skiest, D; Stanford, J; Staszewski, S; Stryker, R; Tashima, KT | 1 |
| Staszewski, S | 1 |
| Katlama, C | 1 |
| Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
| Casado, JL; Moreno, S | 1 |
| Baumann, P; Decosterd, LA; Eap, CB; Marzolini, C; Telenti, A; Troillet, N | 1 |
| Anderson, RM; Cane, PA; Ferguson, NM; Pillay, D; Taylor, S | 1 |
| Ahrlund-Richter, L; Britton, S; Larsson, S; Maijgren-Steffensson, C; Sönnerborg, A; Vahlne, A | 1 |
| Falkenberg, J; Gilden, D; Torres, G | 1 |
| Hanna, L | 1 |
| Bartlett, JG; del Rio, C | 1 |
| Bickel, M; Jacobi, V; Rickerts, V; Staszewski, S; Tews, J | 1 |
| Belson, M; Chun, TW; Connors, M; Davey, RT; Dybul, M; Fauci, AS; Hallahan, CW; Herpin, B; Hidalgo, B; Justement, JS; Metcalf, JA; Migueles, SA; Perry, C | 1 |
| Henry, K; Jenny-Avital, E | 1 |
| Fundarò, C; Genovese, O; Rendeli, C; Salvaggio, E; Tamburrini, E | 1 |
| Campelli, A; Indiveri, F; Murdaca, G; Puppo, F; Setti, M | 1 |
| Craig, K | 1 |
| Barceló, M; Domingo, P | 1 |
| Bettendorf, D; Bucy, RP; Chan, E; Evans, T; Gonzalez, CJ; Landay, AL; Phair, JP; Schmitz, JL; Schnizlein-Bick, CT; Spritzler, J; Squires, KE | 1 |
| Kikuchi, Y; Oka, S; Yazaki, H | 1 |
| Fernando, R; Miller, R | 1 |
| Maggiolo, F; Maserati, R; Migliorino, M; Pan, A; Provettoni, G; Rizzi, L; Rizzi, M; Suter, F | 1 |
| Diaz, B; Martín-Carbonero, L; Pérez-Olmeda, M; Soriano, V | 1 |
| Cooley, TP; Modest, GA; Zacks, JF | 1 |
| Bartlett, MG; Fan, B; Stewart, JT | 1 |
| Dusak, BA; Goodwin, SD; Kuritzkes, DR; Rooney, JF; Skowron, G; Squires, KE; Stevens, M; Thompson, MA; Tolson, JM; Yuen, GJ | 1 |
| Bon, I; Borderi, M; Furlini, G; Gibellini, D; La Placa, M; Monari, P; Re, MC; Schiavone, P; Vitone, F | 1 |
| Chemlal, K; de Truchis, P; Devidas, A; Force, G; Mamet, JP; Mechali, D; Praindhui, D; Pulik, M; Rouveix, E; Welker, Y | 1 |
| Atwine, D; Kebba, A; Kityo, C; Mwebaze, R; Nakityo, R; Peter, M | 1 |
| Arnaud, A; Mauboussin, JM; Peyrière, H; Rouanet, I; Vincent, D | 1 |
| Brun, S; Di Mascio, M; Ho, DD; Hogan, C; Hurley, A; Louie, M; Markowitz, M; Perelson, AS; Rooney, J; Ruiz, N; Simon, V; Sun, E | 1 |
| Brault, C; Chennebault, JM; Loison, J; Payan, C; Peigne, M | 1 |
| Becker, MI; D'Aquila, RT; De Gruttola, V; Delapenha, R; Dubé, MP; Fischl, MA; Gedeon, L; Hirsch, MS; Merigan, TC; Murphy, RL; Pettinelli, C; Pollard, RB; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; van der Horst, C; Vella, S | 1 |
| D'Aquila, RT; De Gruttola, V; Gripshover, BM; Haubrich, R; Hirsch, MS; Johnson, VA; Kaul, P; Martinez, AI; McCarty, SD; Merigan, TC; Morse, GD; Nokta, MA; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; Swingle, M; Vella, S | 1 |
| Feinberg, J | 2 |
| Gazzard, BG; Gotch, F; Hand, J; Imami, N; Nelson, M; Pires, A; Portsmouth, S; Stebbing, J | 1 |
| Boyle, BA | 1 |
| Acosta, EP; Gulick, RM; Klingman, KL; Kuritzkes, DR; Lustgarten, S; Maher, WE; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Shikuma, CM; Snyder, S; Squires, KE; Witt, MD | 1 |
| Baseler, M; Beck, I; Coffin, J; Daucher, M; Davey, RT; Dewar, R; Dybul, M; Ehler, L; Fauci, AS; Frenkel, L; Hallahan, CW; Maldarelli, F; Metcalf, JA; Nies-Kraske, E; Palmer, S; Piscitelli, SC; Powers, A; Rock Kress, DM; Weigand, A | 1 |
| Cassol, S; El-Sadr, W; Friedland, G; Jack, C; Karim, QA; Karim, SA; Lalloo, U | 1 |
| Delfraissy, JF; Gatell, JM; Giordano, M; Jemsek, J; Lazzarin, A; Pokrovskiy, V; Powderly, WG; Rivero, A; Rozenbaum, W; Schrader, S; Sension, M; Squires, K; Thiry, A; Vibhagool, A | 1 |
| Cheng, AK; Coakley, DF; DeJesus, E; Gallant, JE; Lu, B; Miller, MD; Pozniak, AL; Staszewski, S; Suleiman, JM; Toole, JJ | 1 |
| De Luca, A; Di Giambenedetto, S | 1 |
| Castillo, SA; DeJesus, E; Farthing, CF; Gough, K; Grinsztejn, B; Madison, SJ; McCarty, D; Schrader, SR; Sension, MG; Shortino, DD; Thomas, DA | 1 |
| Maida, I; Nuñez, M; Soriano, V | 1 |
| Bonny, T; Brand, JD; Brothers, CH; Buendia, CB; Castillo, SA; DeJesus, E; Gerstoft, J; Hernandez, J; Herrera, G; Lanier, ER; Scott, TR; Teofilo, E | 1 |
| Bower, M; Fisher, M; Gazzard, B; Johnson, M; Jones, R; Mandalia, S; Moyle, G; Nelson, M; Orkin, C; Stebbing, J | 1 |
| del Rio, C | 1 |
| Badaro, R; de Wet, J; Hall, DB; Huisamen, CB; Lange, JM; Montaner, JS; van Leth, F; Vandercam, B; Wit, FW | 1 |
| Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK | 1 |
| Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F | 1 |
| Cahn, P; Castillo, SA; Craig, C; DeJesus, E; Gordon, DN; Moyle, GJ; Scott, TR; Zhao, H | 1 |
| Balakrishnan, P; Carpenter, CC; Cecelia, A; Flanigan, TP; Kumarasamy, N; Mayer, KH; Solomon, S; Vallabhaneni, S | 1 |
| Gazzard, BG; McCormick, K; Moyle, GJ; Osorio, J; Portsmouth, SD | 1 |
| Andreoli, A; Bandelier, C; Bianchi-Demicheli, F; Damsa, C; Lazignac, C; Maris, S; Vidailhet, P | 1 |
| Davis, EA; DeJesus, E; Hill-Zabala, C; Lang, J; Lanier, ER; Liao, Q; Markowitz, M; Shaefer, M | 1 |
| Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
| Baird, I; Cohen, C; Elion, R; Green, L; Green, S; Schrader, S; Ward, D | 1 |
| Amel, EB; Amel, LO; Amine, SM; Asma, J; Fethi, T; Mohamed, C; Mounira, G; Taoufik, BC | 1 |
| Barroso, PF; Boechat, LJ; Melo, MF; Schechter, M; Vettore, MV | 1 |
| Arendt, V; Fundira, L; Lemmer, P; Omes, C; Schneider, S; Schuman, M; Tayari, JC; Wennig, R | 1 |
| Billaud, E; Bugnon, F; Cua, E; Cuzin, L; Dellamonica, P; Delpierre, C; Massip, P; Pugliese, P; Raffi, F | 1 |
| Baker, A; Crawford, W; Jassen, A; Jooste, JP; Van Zyl, AJ | 1 |
| Arathoon, E; Arlotti, M; Giordano, M; Jemsek, JG; Noor, MA; Perez, C; Pokrovskiy, V; Soccodato, M; Sosa, N; Thiry, A | 1 |
| Black, FT; Jørgensen, LB; Kjems, J; Mohey, R; Møller, BK; Obel, N; Tolstrup, M | 1 |
| Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Bonjoch, A; Bravo, I; Clotet, B; Heilek-Sneider, GM; Martinez-Picado, J; Moltó, J; Negredo, E; Ruiz, L; Valle, M | 1 |
| Fisher, M; Gazzard, B; Higgs, C; Johnson, M; Mandalia, S; Moyle, G; Nelson, M; Teague, A | 1 |
| Beijnen, JH; Boron-Kaczmarska, A; Hall, DB; Huitema, AD; Johnson, D; Kappelhoff, BS; Lange, JM; Leith, J; Leth, FV; Livrozet, JM; Losso, MH; Saag, MS; Wit, FW | 1 |
| Boscacci, RT; Buclin, T; Furrer, H; Fux, CA | 1 |
| Hall, DB; Lange, JM; Reiss, P; van Leth, F | 1 |
| Acosta, EP; Bastow, B; Carlson, M; Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Lalama, C; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Schouten, J; Shikuma, CM; Squires, KE | 1 |
| Cheng, A; Lu, B; Margot, NA; Miller, MD | 1 |
| Brothers, CH; Castillo, SA; Hernandez, JE | 1 |
| Bartlett, JA; Griffith, S; Herrera, G; Irlbeck, D; Johnson, J; Liao, Q; Rodriguez, A; Shaefer, MS; Sosa, N | 1 |
| Friedland, G; Jack, C; Khoo, S; Lalloo, U | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Alonso, C; Aranda, M; Barrufet, P; Berenguer, J; Crespo, M; del Río, L; Delegido, A; Ferrer, E; Fisac, C; Gatell, JM; Lérida, A; Llibre, JM; Lonca, M; Martínez-Lacasa, J; Merino, E; Niubo, J; Pedreira, JD; Podzamczer, D; Pulido, F; Ribas, MA; Ribera, E; Rubio, R; Sanchez, P; Sanz, J; Veloso, S | 1 |
| Han, N; Lan, MD; Liu, ZY; Lu, LH; Wei, HS; Yao, J; Zhang, FJ; Zhao, HX | 1 |
| Aguilar, I; Hidalgo, A; Palacios, R; Santos, J | 1 |
| Bastow, B; Glesby, MJ; Gulick, RM; Kuritzkes, DR; Meyer, WA; Ribaudo, HJ; Shikuma, CM; Tashima, KT; Webb, N; Yang, Y | 1 |
| Diller, R; Thompson, K | 1 |
| Galli, M; Gervasoni, C; Grinelli, E; Ortu, M; Rusconi, S; Vigano, O | 1 |
| Asiimwe, F; Behumbiize, P; Brooks, JT; Forna, F; Liechty, CA; Mermin, J; Solberg, P; Tong, T; Weidle, PJ; Were, W | 1 |
| Bekker, V; Jurriaans, S; Kuijpers, TW; Lange, JM; Pajkrt, D; Scherpbier, HJ | 1 |
| Jaruratanasirikul, S; Mahatthanatrakul, W; Ridtitid, W; Sriwiriyajan, S | 1 |
| Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Meyer, WA; Reichman, R; Ribaudo, HJ; Riddler, SA; Santana, J; Shikuma, C; Squires, KE | 1 |
| De Munter, P; Schrooten, Y; Van Laethem, K; Van Ranst, M; Van Wijngaerden, E; Vandamme, AM; Verbesselt, R | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Bertelsen, L; Jakobsen, MR; Laursen, A; Mohey, R; Obel, N; Ostergaard, L; Tolstrup, M | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Amorim, AP; Campos, CP; Custódio, FL; Ferrão, SB; Fonseca, BA; Gaspar, GG; Golin, NA; Marangoni, AT; Melo, Ld; Morejón, KM; Ponzi, CC; Santana, RC; Vanni, T | 1 |
| Abad, J; Amorós-Quiles, I; Belda, A; Borrás-Blasco, J; Casterá, E; Rosique-Robles, D | 1 |
| Ansari, AW; Heiken, H; Schmidt, RE | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Gulick, RM; Kuritzkes, DR; Ribaudo, HJ | 1 |
| Barrufet, P; Crespo, M; Ferrer, E; Gatell, JM; Llibre, JM; Niubo, J; Podzamczer, D; Sanchez, P; Sanz, J; Veloso, S | 1 |
| Asensi, V; Barreiro, P; de Mendoza, C; Estrada, V; González-Lahoz, J; Jiménez-Nacher, I; Palacios, R; Rivas, P; Rodríguez-Novoa, S; Sánchez-Conde, M; Santos, J; Sanz, J; Sola, J; Soriano, V | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; Dejesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Holmes, CB; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Easley, KA; Lennox, JL; Lu, C; Ofotokun, I; Smithson, SE | 1 |
| Balkan, S; Delfraissy, JF; Fernandez, M; Ferradini, L; Laureillard, D; Ly, N; Ngeth, C; Pinoges, L; Prak, N; Puertas, G; Quillet, C; Rouzioux, C; Taburet, AM | 1 |
| Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H | 1 |
| Chaisson, RE; Charalambous, S; Churchyard, GJ; Fielding, KL; Grant, AD; Hoffmann, CJ; Innes, C; Sulkowski, MS; Thio, CL | 1 |
| Asenjo, MA; Barrufet, P; Domingo, P; Gatell, JM; Gutiérrez, F; Knobel, H; Mallolas, J; Pedrol, E; Peñaranda, M; Peraire, J; Pich, J; Vidal, F | 1 |
| Aurpibul, L; Lee, B; Mangklabruks, A; Puthanakit, T; Sirisanthana, T; Sirisanthana, V | 1 |
| de la Torres, J; Gálvez, MC; López, M; López-Cortés, LF; Lozano, F; Palacios, R; Ríos, MJ; Rivero, A; Santos, J | 1 |
| Carosi, G; Ceresoli, F; Cologni, G; Cossarizza, A; Costarelli, S; Gargiulo, F; Lapadula, G; Magoni, M; Manca, N; Nasi, M; Nichelatti, M; Pinti, M; Quiros-Roldan, ME; Torti, C | 1 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| Herrera, L; Moreno, S; Sánchez-de la Rosa, R | 1 |
| Lankoandé, D; Millogo, A; Sawadogo, AB; Yaméogo, AA; Yaméogo, I | 1 |
| Basseila, GB; Bokilo, AD; Dokekias, AE; Galiba, FO; Malanda, F; Nsitou, MB; Ntsimba, P | 1 |
| Balakrishnan, P; Kumarasamy, N; Murugavel, KG; Priya, B; Saghayam, S; Shankar, EM; Solomon, S; Sundaram, M; Venkatesh, KK | 1 |
| Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA | 1 |
| Cotter, BR; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Gerschenson, M; Komarow, L; Mitchell, CK; Murphy, RL; Parker, RA; Squires, K; Stein, JH; Torriani, FJ | 1 |
| Amin, J; Avihingsanon, A; Bowden, S; Cooper, DA; Dore, GJ; Lewin, SR; Locarnini, S; Marks, P; Matthews, GV; Petcharapirat, P; Rerknimitr, R; Ruxrungtham, K; Sasadeusz, J | 1 |
| Ajayi, SO; Akingbola, TS; Brown, BJ; Oladokun, R; Omigbodun, OO; Osinusi, K | 1 |
| Angels Ribas, M; Asensi, V; Berenguer, J; Domingo, P; Gimeno, JL; González, J; Miralles, P; Pedrol, E; Pérez-Molina, JA; Ribera, E; Santamaría, JM; Santos, J; Terrón, JA | 1 |
| Angel, JB; Fätkenheuer, G; Greaves, W; Hoffmann, C; Horst, H; Landovitz, RJ; Long, J; Opravil, M | 1 |
| Cosin, J; Crespo, M; Domingo, P; Galindo, MJ; García-Alcalde, ML; Garrido, M; Geijo, P; López-Aldeguer, J; Lozano, F; Muñoz, A; Pedrol, E; Ribera, E; Roca, B; Sánchez, T; Suárez-Lozano, I; Teira, R; Terrón, A; Vergara, A; Viciana, P; Vidal, F; Viladés, C | 1 |
| Burgisser, P; Cavassini, M; Giulieri, SG; Günthard, HF; Knoepfel, SA; Metzner, KJ; Rauch, P; Yerly, S | 1 |
| George, C; Jayakumar, B; Lal, L; Yesoda, A | 1 |
| Moreno, V; Valencia, ME | 1 |
| Cabié, A; Chêne, G; Girard, PM; Katlama, C; Mercié, P; Michelet, C; Monchecourt, F; Morand-Joubert, L; Pétour, P; Trylesinski, A; Verdon, R | 1 |
| Borroto-Esoda, K; Harris, J; Lansdon, EB; Miller, MD; O'Neal, W; Svarovskaia, ES; Wakeford, C; Waters, JM; White, KL | 1 |
| Dewar, R; Dybul, M; Kityo, C; Mbamanya, F; Mugyenyi, P; Quinn, TC; Reynolds, SJ; Ssali, F | 1 |
| Bernstein, BM; Brown, TT; da Silva, BA; King, MS; McComsey, GA; Qaqish, RB | 1 |
| Ebrahimi, R; Ewan, J; Fisher, M; Kingston, M; Liu, H; Moyle, GJ; Orkin, C; Reilly, G; Shahmanesh, M; Wilkins, E | 1 |
| Arribas López, JR | 1 |
| Dieng, AB; Diop, BM; Diop, SA; Diouf, A; Fall, MB; Lakh, A; Ndiaye, I; Niang, Kh; Seydi, M; Soumaré, M; Sow, A; Sow, PS; Tekpa, G | 1 |
| Kongnyuy, EJ; Shang, J; Shey, M; Wiysonge, CS | 1 |
| Hanekom, WA; Maartens, G; Meintjes, G; Rangaka, MX; Seldon, R; Wilkinson, KA; Wilkinson, RJ | 1 |
| Cheng, AK; Enejosa, J; Margot, NA; McColl, DJ; Miller, MD | 1 |
| Boccafoglio, F; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Soldani, F | 1 |
| Karunaianantham, R; Narayanan, PR; Rajesh, L; Swaminathan, S | 1 |
| Louie, M; Marfatia, S; Mear, I; Meunier, J; Regnault, A; Viala-Danten, M | 1 |
| Bravo, I; Carosi, G; Clotet, B; del Arco, A; Echeverría, P; Gálvez, J; Gómez, JL; López, JC; López-Blazquez, R; Mariño, A; Moreno, A; Negredo, E; Ocampo, A; Pedrol, E; Pérez-Alvarez, N; Portilla, J; Prieto, A; Rubio, R; Viladés, C | 1 |
| Asahchop, EL; Brenner, BG; Moisi, D; Ntemgwa, M; Toni, TA; Wainberg, MA | 1 |
| Boothby, M; Gathercole, LL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Umpleby, AM | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Cooper, V; Fisher, M; Gellaitry, G; Horne, R; Lange, AC; Vrijens, B; White, D | 1 |
| Clumeck, N; Coakley, E; Cooper, DA; Dejesus, E; Goodrich, J; Hackman, F; Heera, J; Horban, A; Ive, P; Mayer, H; Mingrone, H; Mohapi, L; Reeves, JD; Reyes-Teran, G; Saag, M; Sullivan, J; Tawadrous, M; Ting, N; Van Der Ryst, E; Walmsley, S; Westby, M | 1 |
| Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
| Campo, RE; Cohen, C; Grimm, K; Maa, J; Seekins, D; Shangguan, T | 1 |
| Deshpande, A; Fleury, HJ; Jeannot, AC; Pinson, P; Schrive, MH; Wittkop, L | 1 |
| Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C | 1 |
| Bichet, JC; Delfraissy, JF; Ghosn, J; Sahali, S | 1 |
| Bardin, C; Blanche, S; Bouazza, N; Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Ouiminga, A; Rouet, F; Tréluyer, JM; Urien, S; Van De Perre, P; Zoure, E | 1 |
| Gerstoft, J; Hansen, AB; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Aba, YT; Aoussi, EF; Bissagnene, E; Eholié, SP; Ehui, E; Kadio, A; Kakou, AR; Kassi, A; Ondounda, M; Ouattara, I; Tanon, A | 1 |
| Castelnuovo, B; Kamya, MR; Kiragga, A; Manabe, Y | 1 |
| Bachani, D; Chan, PL; Deshpande, A; Rajasekaran, S; Rewari, BB; Srikantiah, P | 1 |
| Rutherford, GW; Siegfried, N; Spaulding, A | 1 |
| Dhlomo, S; Emery, S; Grandits, G; Khabo, P; Khanyile, T; Komati, S; Magongoa, D; Naidoo, LC; Neaton, JD; Polis, M; Qolohle, D; Ratsela, A | 1 |
| Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB | 1 |
| Adkison, K; Bakeera-Kitaka, S; Burger, D; Gibb, DM; Kekitiinwa, A; Kendall, L; Mugyenyi, P; Musiime, V; Musoke, P; Odongo, F; Snowden, WB; Thomason, M; Walker, AS | 1 |
| Borroto-Esoda, K; Goodman, DD; Margot, NA; McColl, DJ; Miller, MD; Svarovskaia, ES; Zhong, L; Zhou, Y | 1 |
| Alvarez, SM; de Jesús Asencio Montiel, I; Flores, RA; Martínez, JG; Mata Marín, JA | 1 |
| Honda, M; Ishisaka, M; Ishizuka, N; Kimura, S; Oka, S | 1 |
| Cooper, V; Ewan, J; Fisher, M; Horne, R; Liu, HC; Moyle, GJ; Reilly, G | 1 |
| Anh, DT; Bang, ND; Chau, NV; Chau, TT; Chinh, NT; de Jong, M; Dong, DT; Dung, NH; Dung, NT; Farrar, JJ; Hai, NN; Hien, NQ; Hien, TT; Lan, NN; Lan, NT; Mai, NT; Mai, PP; Minh, NH; Phu, NH; Quy, HT; Simmons, CP; Thai, PV; Thoa, NT; Tien, NA; Török, ME; Wolbers, M; Yen, NT | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Dlamini, J; Hadigan, C; Khabo, P; Kowo, H; Ledwaba, L; Maja, P; Mokhathi, T; Mokwena, N; Orsega, S; Proschan, M; Tsoku, M | 1 |
| Dia, AT; Diallo, PD; Gaye, AM; Sow, PG | 1 |
| Donnelly, J | 1 |
| Barro, M; Diagbouga, S; Diasso, Y; Drabo, A; Foulongne, V; François, R; Hien, A; Hien, H; Michel, S; Msellati, P; Nacro, B; Ouiminga, A; Some, J; Tamboura, H; Van De Perre, P; Yaméogo, S; Zouré, E | 1 |
| Calis, JC; de Wit, TF; Geelen, SP; Sigaloff, KC; van Vugt, M | 1 |
| Balungi, J; Burger, DM; Bwakura-Dangarembizi, M; Ferrier, A; Fillekes, Q; Gibb, DM; Keishanyu, R; Kendall, L; Lutakome, J; Natukunda, E; Walker, AS | 1 |
| González-Duarte, A; Pinales, R; Ramirez, C; Sierra-Madero, J | 1 |
| Anwikar, SR; Bandekar, MS; Kshirsagar, NA; Pazare, AP; Smrati, B; Tatke, PA | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Klinbuayaem, V; Munsakul, W; Petoumenos, K; Prasithsirikul, W; Ruxrungtham, K; Sirivichayakul, S; Sungkanuparph, S | 1 |
| Beck-Sagué, CM; Fernandez, AD; Leonardo-Guerrero, J; Nicholas, SW; Roman-Pouriet, J; Schmidt, NC | 1 |
| Aboulker, JP; Bocquentin, M; Charreau, I; Izopet, J; Marchou, B; Molina, JM; Taburet, AM; Tangre, P; Trancart, S | 1 |
| Conradie, F; Fox, M; Ive, P; McIntyre, J; Orrell, C; Papathanasopolous, MA; Sanne, I; Stevens, W; Wallis, CL; Wood, R; Zeinecker, J | 1 |
| Bessong, PO; Masebe, TM; Meyer, D; Ndip, RN; Nwobegahay, J | 1 |
| Kanki, PJ; Shafer, RW; Tang, MW | 1 |
| Agu, KA; Akpoigbe, KJ; Badru, T; Chabikuli, O; Eluwa, GI; Hamelmann, C | 1 |
| Arasteh, K; Boven, K; Crauwels, H; De Wet, J; Gathe, J; Gold, J; Hodder, S; Kumar, P; Mohapi, L; Short, W; Vanveggel, S | 1 |
| Luaengniyomkul, A; Mankhatitham, W; Manosuthi, W | 1 |
| Bloom, A; Brown, TT; Daar, ES; Fedarko, N; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C | 1 |
| Goliath, R; Meintjes, G; Seldon, R; Wilkinson, KA; Wilkinson, RJ | 1 |
| Shah, I | 1 |
| Jaye, A; Oko, F; Okomo, U; Peterson, I; Peterson, K; Togun, T; Townend, J | 1 |
| Akinkuotu, A; Chasela, C; Hosseinipour, MC; Jamieson, DJ; Johnson, DC; King, CC; Kourtis, AP; Maliwichi, M; Moses, A; Mwafongo, A; van der Horst, C | 1 |
| Carda-Broch, S; Casas-Breva, I; Esteve-Romero, J; Peris-Vicente, J; Rambla-Alegre, M | 1 |
| Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB | 1 |
| Chersich, M; Fairlie, L; Kuhn, L; Meyers, T; Moultrie, H; Palmer, M | 1 |
| Agbaji, O; Ekong, E; Graham, C; Hawkins, C; Idoko, J; Kanki, P; Meloni, S; Muazu, M; Murphy, R; Nimzing, L; Sankalé, JL; Thio, CL | 1 |
| Bissek, AC; Defo, D; Kouotou, EA; Mboua, JB | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Basse, CD; Dia, NM; Dieng, AB; Diop, BM; Diop, SA; Fortes-Déguénonvo, L; Manga, NM; Ndaw, G; Ndour, CT; Seydi, M; Soumaré, M; Sow, PS | 1 |
| Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Bayonne Kombo, ES; Gathse, A | 1 |
| Alexander, AJ; Hooker, TF; Tomasella, FP; Zhang, L | 1 |
| Alobwede, SM; Kongnyuy, EJ; Shey, MS; Wiysonge, CS | 1 |
| Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
| Bedogni, G; Cococcioni, L; Fabiano, V; Giacomet, V; Mora, S; Stucchi, S; Viganò, A; Zuccotti, GV | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| Blanche, S; Bouazza, N; Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Ouiminga, A; Rouet, F; Tréluyer, JM; Urien, S; Van de Perre, P; Zoure, E | 1 |
| Abgrall, S; Antinori, A; Cavassini, M; Costagliola, D; Crane, HM; Gill, MJ; Gomez Sirvent, JL; Guest, JL; Ingle, SM; Manzardo, C; May, MT; Mercie, P; Mugavero, MJ; Phillips, A; Reekie, J; Reiss, P; Saag, MS; Samji, H; Stephan, C; Sterling, TR; Sterne, JA; Tate, J; Wasmuth, JC | 1 |
| Boonsuk, S; Butchon, R; Chokephaibulkit, K; Kullert, N; Kulpeng, W; Phanuphak, N; Pilasant, S; Tantivess, S; Teerawattananon, Y; Tosanguan, K; Voramongkol, N; Werayingyong, P | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G | 1 |
| DeJesus, E; Edelstein, H; Felizarta, F; Ha, B; Hao, R; Huhn, G; Kumar, P; Pappa, K; Ross, L; Sloan, L; Small, CB; Stancil, B | 1 |
| Bekker, LG; Gupta-Wright, A; Lawn, SD; Wood, R | 1 |
| Cortes, CP; Otto-Knapp, R; Saavedra, F; Weitzel, T; Wolff, M | 1 |
| Cardoso, SV; de Faria, PR; Loyola, AM; Servato, JP; Spini, PH; Spini, TH | 1 |
| Arribas, JR; Compston, J; Domingo, P; Gartland, M; Granier, C; Moyle, GJ; Orkin, C; Pearce, H; Sedani, S; Stellbrink, HJ | 1 |
| Ahmed-Jushuf, I; Arumainayagam, J; Carlin, EM; Chandramani, S; Das, S; Ghanem, M; Kumari, B; Pammi, M; Riddell, L | 1 |
| Ampofo, WK; Barnor, JS; Brandful, JA; Ibe, S; Ishikawa, K; Nii-Trebi, NI; Ofori, SB; Sugiura, W; Yamaoka, S | 1 |
| Crowther, NJ; Dickens, C; Dix-Peek, T; Duarte, R; Evans, D; Menezes, CN; Prinsloo, A; Raal, F; Rassool, M; Sanne, I; Van Amsterdam, D | 1 |
| Bertrand, J; Blanc, FX; Borand, L; Chea, P; Chou, M; Mentré, F; Nay, KH; Taburet, AM; Verstuyft, C | 1 |
| de Oliveira, T; Lessells, RJ; Manasa, J; McGrath, N; Naidu, KK; Newell, ML; Skingsley, A | 1 |
| Bansi-Matharu, L; Bibby, D; Bulteel, N; Churchill, D; Dunn, D; Hill, T; Nelson, M; Sabin, C | 1 |
| Chappuy, H; Diagbouga, S; Drabo, A; Hien, A; Hien, H; Meda, N; Msellati, P; Nacro, B; Nicolas, J; Ouiminga, A; Rouet, F; Somé, J; Tamboura, H; Van de Perre, P; Yaméogo, S; Zoure, E | 1 |
| Chamnanphon, M; Jantararoungtong, T; Koomdee, N; Manosuthi, W; Prommas, S; Puangpetch, A; Santon, S; Sukasem, C | 1 |
| Aklillu, E; Gustafsson, LL; Kuteesa, RB; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Owen, JS; Ross, C; Sewankambo, N; Thabane, L | 1 |
| Choun, K; De Weggheleire, A; Lynen, L; Phirum, L; Thai, S; van Griensven, J | 1 |
| Aghokeng, AF; Chia, JE; Delaporte, E; Einterz, E; Eymard-Duvernay, S; Molina, JM; Mpoudi-Ngole, E; Peeters, M; Taieb, F | 1 |
| Chimbwandira, FM; Chirwa, Z; Crampin, AC; Dasgupta, AN; Glynn, JR; Jahn, A; Katundu, C; Kayange, M; Koole, O; Price, AJ; Saul, JL; Zaba, B | 1 |
| Crowe, SM; David, M; Gare, J; Hearps, AC; Imara, U; Kaima, P; Kelly-Hanku, A; Kombati, Z; Ryan, CE; Siba, PM; Timbi, D | 1 |
| Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C | 1 |
| Arribas, J; Deckx, H; Duiculescu, D; Florence, E; Hung, CC; Sension, M; Stevens, M; Tebas, P; Vanveggel, S; Wilkin, T | 1 |
| Brown, LA; Ferrell, D; Giunta, B; Jin, J; Obregon, D; Sadic, E; Smith, AJ; Tan, J | 1 |
| Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Holla, P; Jameel, S; Munshi, SU; Panda, H; Rewari, BB | 1 |
| Bethell, R; Colby-Germinario, SP; Oliveira, M; Rajotte, D; Wainberg, MA; Xu, HT | 1 |
| Antonopoulou, S; Chini, M; Demopoulos, CA; Fragopoulou, E; Gargalianos, P; Lazanas, MC; Mangafas, N; Papakonstantinou, VD; Psarra, K; Stamatakis, GM; Tsogas, N; Tsoupras, AB | 1 |
| Gui, T; Guo, W; Jia, L; Jiao, L; Li, H; Li, J; Li, L; Liu, S; Liu, Y; Zhuang, D | 1 |
| Berendes, S; Campbell, TB; Cardoso, SW; Christian, P; Gupta, A; Gupte, N; Kanyama, C; Lama, JR; Mwelase, N; Pillay, S; Riviere, C; Samaneka, W; Semba, RD; Shivakoti, R; Sugandhavesa, P; Tang, AM; Yang, WT | 1 |
| Chen, Z; Huang, JD; Lee, SS; Wu, H; Zhang, HJ; Zhang, Q; Zhang, XM; Zheng, BJ | 1 |
| Back, DJ; Burger, D; Lamorde, M; Schapiro, JM | 1 |
| Anderson, J; Dhar, J; Ebrahimi, R; Ewan, J; Fisher, M; Moyle, GJ; Orkin, C; Wang, H; Wilkins, E | 1 |
| Alonso-Villaverde, C; Ferrer, E; Martinez-Picado, J; Maso, M; Muñoz-Moreno, JA; Ouchi, D; Podzamczer, D; Prats, A; Puertas, MC; Rozas, N; Tiraboschi, JM | 1 |
| Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O | 1 |
| Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I | 1 |
| Fan, P; Li, J; Li, N; Liang, Y; Ma, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q | 1 |
| Aris, E; Baernighausen, T; Chalamilla, G; Fawzi, W; Hertzmark, E; Jackson, E; Machumi, L; Muya, A; Mwanyika-Sando, M; Sando, D; Spiegelman, D | 1 |
| Avi, R; Huik, K; Jõgeda, EL; Kallas, E; Karki, T; Lutsar, I; Margus, T; Pauskar, M | 1 |
| Antony, J; Arumugam, K; D'Souza, G; De Costa, A; Kumar, DS; Kumarasamy, N; Poongulali, S; Rewari, BB; Shastri, S; Shet, A | 1 |
| Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS | 1 |
| Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Thongyen, S | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Mancini, R; Motta, R; Re, MC; Viale, P | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Andreotti, M; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Marchei, E; Mwenda, R; Palombi, L; Pichini, S; Pirillo, MF; Sagno, JB; Vella, S | 1 |
| Alanio, A; De Castro, N; Gaube, G; Gueguen, A; Lascoux, C; Molina, JM; Zagdanski, AM | 1 |
| Cai, WP; He, HL; Huang, SB; Ling, XM; Liu, YF; Wang, H; Wang, M; Wang, XC; Wei, FL; Wu, H; Wu, YS; Wu, ZY; Yang, L; Zhang, FJ; Zhang, WW | 1 |
| Aklillu, E; Bisaso, RK; Gustafsson, LL; Mukonzo, JK; Ogwal-Okeng, J; Owen, JS | 1 |
| Cheng, X; Fraenkel, L; Han, Y; Hsieh, E; Insogna, KL; Li, T; Xia, W; Yin, MT; Zhu, T | 1 |
| Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; Duarte, G; Ferriani, RA; Prandini, TR; Quintana, SM; Ragazini, CS; Vieira, CS | 1 |
| Alves, LDS; Nadvorny, D; Rolim-Neto, PJ; Soares, MFR; Soares-Sobrinho, JL | 1 |
| Belyhun, Y; Liebert, UG; Maier, M | 1 |
| Amici, R; Andreotti, M; Buonomo, E; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Scarcella, P; Vella, S | 1 |
| Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
| Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N | 1 |
| García-Arieta, A; Gordon, J; Gwaza, L; Leufkens, H; Potthast, H; Stahl, M; Welink, J | 1 |
| Amariles, P; Galindo, J; Galindo-Orrego, X; González-Avendaño, S; Hincapié, JA; Mueses-Marín, HF | 1 |
| Abach, J; Abongomera, G; Chabala, C; Colebunders, R; Cook, A; Gibb, DM; Kekitiinwa, A; Kityo, C; Lamorde, M; Mulenga, V; Musiime, V; Thomason, M; Walker, AS | 1 |
| Alioni, S; Izudi, J; Kerukadho, E; Ndungutse, D | 1 |
| Bienczak, A; Bouazza, N; Burger, D; Capparelli, EV; Cressey, TR; Denti, P; Foissac, F; Lallemant, M; McIlleron, H; Penazzato, M; Treluyer, JM; Urien, S | 1 |
| Brophy, JC; Chan, AK; Hawkes, MT; Mateyu, G; Mwinjiwa, E; Sodhi, SK | 1 |
| Asari, V; Baxter, C; Garrett, N; Grobler, A; Karim, QA; Karim, SSA; Majola, N; Naicker, N; Naidoo, A; Werner, L | 1 |
| Clumeck, N; de Oliveira, T; Gregson, J; Gupta, RK; Hamers, RL; Hoffmann, CJ; Hunt, G; Kaleebu, P; Kanki, P; Kantor, R; Kerschberger, B; Lockman, S; Marconi, VC; Ndembi, N; Pillay, D; Raizes, E; Shafer, RW; van Vuuren, C; Yang, C | 1 |
| Kondapi, AK; Kumar, P; Lakshmi, YS | 1 |
| Naidoo, P; Soorju, V | 1 |
| Badal-Faesen, S; Brown, TT; Campbell, TB; Cardoso, SW; Erlandson, KM; Fiorillo, SP; Hakim, J; Kumarasamy, N; Kumwenda, J; Lalloo, U; Riviere, C; Sanchez, J | 1 |
| Amani-Bosse, C; Amorissani-Folquet, M; Avit, D; Blanche, S; Coulibaly, M; Dahourou, DL; Eboua, F; Kalmogho, A; Lepage, P; Leroy, V; Malateste, K; Meda, N; N'Gbeche, S; Ouédraogo, R; Ouédraogo, S; Salamon, R; Seguin-Devaux, C; Timité-Konan, M; Toni, T; Van de Perre, P; Yonaba, C | 1 |
| Maartens, G; Martinson, NA; Mochan, A; Muchichwa, P; Norman, J; Rakgokong, M; Sigauke, FR; Variava, E | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Avihingsanon, A; Burger, DM; Gatechompol, S; Maek-A-Nantawat, W; Ruxrungtham, K; Sapsirisavat, V; Sophonphan, J; Thammajaruk, N; Thiansanguankul, W; Ubolyam, S | 1 |
| Awoke, T; Birlie, B; Braekers, R; Kasim, A; Shkedy, Z | 1 |
| Barrow, G; Camacho, R; Carmona, S; Grant, PM; Gupta, RK; Hamers, RL; Harrigan, PR; Jordan, MR; Kantor, R; Katzenstein, DA; Kuritzkes, DR; Maldarelli, F; Otelea, D; Paredes, R; Schapiro, JM; Shafer, RW; Tzou, PL; van Zyl, G; Wallis, CL | 1 |
| Andolina, A; Carbone, A; Castagna, A; Franzin, M; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Muccini, C; Oltolini, C; Poli, A; Spagnuolo, V; Tadini, P | 1 |
| Brambilla, D; Ceffa, S; De Luca, A; Liotta, G; Luhanga, R; Magid, NA; Mancinelli, S; Marazzi, MC; Palombi, L; Sidumo, ZJ; Zanelli, G | 1 |
| Cotarelo, M; Macías, J; Mancebo, M; Merchante, N; Merino, D; Montes-Ramírez, ML; Pérez-Pérez, M; Pineda, JA; Pulido, F; Raffo, M; Rivero-Juárez, A; Téllez, F | 1 |
| Abalem, MF; Carricondo, PC; Rao, RC | 1 |
| Janabi, M; Kabeho, A; Mayala, H; Nicholaus, P; Nkinda, A; Pallangyo, P | 1 |
| Ahmadi, NE; Ahsani-Nasab, S; Bayanolhagh, S; Esmaeilzadeh, A; Lolaie, M; Moallemi, S; Mohraz, M; Narouei, A; Sadeghi, L; SeyedAlinaghi, S; Tabatabai, RA | 1 |
| Awodele, O; Oshikoya, KA; Popoola, TD | 1 |
| Castelnuovo, B; Gonza, P; Kambugu, A; Kiragga, AN; Mbabazi, O; Mubiru, F; Musomba, R; Ratanshi, RP | 1 |
| Chetty, T; Coutsoudis, A; Thorne, C | 1 |
| Bourrel, R; Lapeyre-Mestre, M; Montastruc, JL; Rwagitinywa, J; Sommet, A | 1 |
| Bonolo, PF; Ceccato, MDGB; Costa, JO; Dos Santos, H; Mendes, JC; Reis, AMM; Silveira, MR | 1 |
| Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA | 1 |
| Dubrocq, G; Rakhmanina, N | 1 |
| Appiah, LT; Beloukas, A; Chadwick, D; Geretti, AM; Phillips, RO; Ruggiero, A; Sarfo, FS; Smith, C; Stockdale, AJ; Villa, G | 1 |
| Abrams, EJ; Arpadi, S; Mogashoa, M; Mutiti, A; Nxele, M; Pepeta, L; Rivadeneira, ED; Sogaula, N; Teasdale, CA; Wang, C; Yuengling, KA | 1 |
| Ceckova, M; Deutsch, B; Fromm, MF; Reznicek, J; Staud, F | 1 |
| Akakpo, AS; Bassowa, A; Dapam, AN; Kombaté, K; Laouali, AY; Mahamadou, G; Mensah, E; Mouhari-Toure, A; Pitché, P; Saka, B; Teclessou, JN | 1 |
| Mugusi, S; Ngaimisi, E; Sasi, P; Sungi, SS; Ulenga, N | 1 |
| Chendi, BH; Eyoh, A; Ikomey, GM; Jacobs, GB; Lyonga, E; Mesembe, M; Okomo Assoumou, MC; Yekwa, EL | 1 |
| Abebo, TA; Altaye, AA; Asfaw, FT; Bekele, FB; Hibistu, DT; Kebede, HG; Laelago, T; Lukas, K; Tesfaye, DJ; Turuse, EA | 1 |
| Hwang, C; Martin, EA; Orkin, C | 1 |
| Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Huang, JP; Huang, WH; Luo, SD; Luo, XL; Mo, LD; Ni, ZY; Su, GS; Su, HZ; Wu, JY | 1 |
| Amariles, P; Castañeda, C; Galindo, J; Mueses-Marín, HF | 1 |
| Boulware, DR; Lukande, R; Meya, DB; Namuju, OC; Nicol, MR; Pastick, KA; Rhein, J; Taylor, J; Williams, DA | 1 |
| Boyer, S; Calmy, A; Delaporte, E; Eymard-Duvernay, S; Kouanfack, C; Leroy, S; Mpoudi-Etame, M; Omgba Bassega, P; Peeters, M | 1 |
| Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, AN; Limarzi, L; Ngongondo, M; Wallie, SD | 1 |
| Adebisi, SA; Adedeji, NO; Adedeji, TA | 1 |
| Chen, IT; Chen, JK; Chen, YS; Lee, SS; Sy, CL; Tsai, HC; Tseng, YT; Weng, YW; Wu, KS | 1 |
| Boricic, I; Dimitrijevic, B; Dragovic, G; Jevtovic, D; Nikolic, K; Salemovic, D; Tomanovic, N | 1 |
| Bela, B; Ibrahim, F; Kusumaningrum, A; Yunihastuti, E | 1 |
| Chadwick, EG; Correia, KF; Crowell, CS; DiPerna, A; Hazra, R; Seage, GR; Smith, R; Van Dyke, RB; Williams, PL; Yildirim, C | 1 |
| Diani, E; Gibellini, D; Lanzafame, M; Lattuada, E; Luise, D; Vecchi, M; Vincenzi, M | 1 |
| Li, A; Li, C; Li, H; Li, W; Li, X; Xia, W | 1 |
| George, PE; Mercedes, R; Nabukeera-Barungi, N; Otto, SBJ | 1 |
| Arellano, J; Corredoira, Y; Gonzalez, R; Nuñez, R | 1 |
| Jiang, F; Lu, Z; Su, Q; Tang, Y; Wei, S; Zhou, Z | 1 |
| Azmi, M; Baber, ZU; Badlani, S; Dodani, SK; Nasim, A; Sheerani, M | 1 |
| He, J; Ma, R; Sun, S; Xu, B; Zhang, Q; Zhang, Y; Zhao, CS | 1 |
| Anthony, P; Best, BM; Cahn, P; Chakhtoura, N; Chokephaibulkit, K; Cressey, TR; de Lourdes B Teixeira, M; Essack, Z; Frenkel, LM; Fuller, TL; Gouvèa, MIS; Hennessy, R; João, EC; Laimon, L; Mathiba, R; Mirochnick, M; Mmbaga, BT; Moreira, LF; Morrison, RL; Ngocho, JS; Njau, BN; Pilotto, JHS; Prommas, S; Rolon, MJ; Shapiro, DE; Siberry, GK; Violari, A; Werarak, P | 1 |
| Afolayan, S; Agumah, R; Akang, E; Akanmu, AS; Dosumu, O | 1 |
| Byakika-Kibwika, P; Kalyesubula, R; Nyende, L; Sekasanvu, E | 1 |
| Chang, SY; Chen, YT; Chen, YW; Huang, CK; Huang, SH; Huang, WC; Hung, CC; Lin, SW; Liu, WC; Ou, ST; Sun, HY | 1 |
| Abdool Karim, Q; Dawood, H; Mansoor, LE; Matten, D; Naicker, CL; Naidoo, K; Singo, D; Williamson, C | 1 |
| Jianwei, L; Menghua, W; Qinwei, Y; Xin, Z; Yu, Z | 1 |
| Cai, WP; Deng, XZ; Hu, FY; Lan, Y; Li, F; Li, LH; Nie, Y | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Betha, TP; Dravid, A; Dravid, M; Gawali, R; Kore, S; Kulkarni, M; Mahajan, U; Rathod, N; Saraf, C; Sharma, AK | 1 |
| Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
| Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A | 1 |
| Benamor Teixeira, ML; Chakhtoura, N; Coombs, RW; Frenkel, LM; Fuller, TL; Gouvêa, MI; Hennessey, R; João, EC; Mirochnick, M; Morrison, RL; Shapiro, DE; Whitson, K | 1 |
| Aghasadeghi, MR; Ardestani, MS; Nikbin, M; Pargoo, EM; Parivar, K; Rahimi, P | 1 |
| Chen, P; Deng, L; Hong, Z; Li, C; Luo, X; Xia, J; Zheng, X; Zhou, L; Zhou, Y | 1 |
| Afonso Reis, E; Almeida-Brasil, CC; Ceccato, MDGB; de Oliveira Costa, J; Rodrigues, VA; Silveira, MR | 1 |
| Amstutz, A; Belus, JM; Brown, JA; Glass, TR; Klimkait, T; Labhardt, ND; Mokhele, K; Muhairwe, J; Nsakala, BL; Rakuoane, I; Tschumi, N | 1 |
| Alhassan, Y; Bokako, S; Burger, D; Byamugisha, J; Byrne, K; Chen, T; Chiong, J; Colbers, A; Hodel, EM; Hu, NC; Khoo, S; Kintu, K; Lamorde, M; Malaba, TR; Mrubata, M; Myer, L; Nakatudde, I; Orrell, C; Read, J; Read, L; Reynolds, H; Seden, K; Stemmet, LA; Taegtmeyer, M; Theunissen, H; Twimukye, A; Waitt, C; Wang, D | 1 |
| Figueredo, CC; Gomes, MP; Juneau, P; Kitamura, RSA; Kubis, GC; Navarro-Silva, MA; Nogueira, KDS; Vieira, F | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
| Abdusalaamu, K; Boulware, DR; Collins, L; Lukande, R; Meya, DB; Mishra, U; Namuju, OC; Nicol, MR; Pastick, KA; Wang, F | 1 |
| Chen, D; Du, Y; Huang, Z; Li, J; Wang, Y; Wen, Z; Yin, S; Zhong, H | 1 |
| Akpomiemie, G; Bosch, B; Chandiwana, N; Hill, A; McCann, K; Mirchandani, M; Qavi, A; Sokhela, S; Venter, WDF | 1 |
| Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y | 1 |
| Abba, A; Beloumou, GA; Billong, SC; Bouba, NP; Ceccherini-Silberstein, F; Chenwi, CA; Colizzi, V; Dambaya, B; Djupsa Ndjeyep, SC; Eben-Moussi, E; Etame, NK; Fokam, J; Ka'e, AC; Kengni, AMN; Kouanfack, C; Meledie, AP; Molimbou, E; Mossiang, L; Ndjolo, A; Nka, AD; Perno, CF; Santoro, MM; Semengue, ENJ; Sosso, SM; Takou, D; Teto, G; Tommo Tchouaket, MC; Yagai, B; Zoung-Kanyi Bissek, AC | 1 |
| Fan, X; Huang, H; Jiao, Y; Li, J; Wang, FS; Yu, XD; Zhang, D | 1 |
| Guan, W; Li, T; Li, Y; Lin, Q; Song, X; Xu, Y; Yu, W; Zhang, Y; Zhang, Z | 1 |
| Fang, Z; Gang, X; Guoqiang, Z; Jing, C; Min, W; Ning, W; Wei, T; Xingzhi, W | 1 |
| Hachey, D; Shiluama, R; Singu, BS; van Woerden, I | 1 |
| Avedissian, SN; Fletcher, CV; Mykris, TM; Podany, AT; Scarsi, KK; Weinhold, J; Winchester, LC | 1 |
| Chinula, L; Corbett, AH; Cottrell, ML; Gajer, P; Haddad, LB; Hurst, S; Kourtis, AP; Lantz, AM; Nelson, JAE; Nicol, MR; Ravel, J; Tang, JH; Tegha, G | 1 |
| Chandiwana, P; Duri, K; Gumbo, FZ; Marere, T; Mataramvura, H; Mazengera, LR; Mazhandu, AJ; Munjoma, PT | 1 |
| Anuradha, S; Bhrusundi, M; Dravid, AN; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; Raveendra, KR | 1 |
| Cao, Y; Chu, M; Huang, H; Li, M; Qin, G; Zhuang, X; Zou, M | 1 |
| Chen, X; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, W; Liu, X; Meng, Q; Pannecouque, C; Zhan, P | 1 |
| Chizhov, AO; Geisman, AN; Khandazhinskaya, AL; Kochetkov, SN; Naesens, L; Novikov, MS; Ozerov, AA; Pannecouque, C; Seley-Radtke, KL; Valuev-Elliston, VT | 1 |
| Cherukupalli, S; De Clercq, E; Fu, Z; Gao, S; Kang, D; Liu, X; Pannecouque, C; Sun, L; Zhan, P; Zhang, T; Zhou, Z | 1 |
20 review(s) available for lamivudine and efavirenz
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
Topics: Acetamides; Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Prodrugs; Pyridones; Reverse Transcriptase Inhibitors; Triazoles | 2019 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Review of NNRTIs: 'today and tomorrow'.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Quality of Life; Reverse Transcriptase Inhibitors | 2006 |
[The "induction-maintenance" strategy].
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Virus Replication; Zidovudine | 2008 |
A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2009 |
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2010 |
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Drug Resistance, Viral; Female; Health Resources; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Latin America; Lopinavir; Male; Mutation; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2011 |
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load; World Health Organization | 2012 |
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2013 |
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Maintenance Chemotherapy; Middle Aged; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2013 |
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Viral; Drug Therapy; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Public Health; Tenofovir | 2014 |
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Congenital Abnormalities; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Network Meta-Analysis; Nevirapine; Perinatal Care; Pregnancy; Pregnancy Complications, Infectious; Stavudine; Stillbirth; Zidovudine | 2018 |
The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Tenofovir | 2018 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
125 trial(s) available for lamivudine and efavirenz
| Article | Year |
|---|---|
Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Viral Load; Zidovudine | 1999 |
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1999 |
Update on study 006--EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Humans; Indinavir; Lamivudine; Lipid Metabolism; Oxazines; Viral Load; Zidovudine | 1999 |
Sustiva combination effective as initial treatment.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Indinavir; Lamivudine; Oxazines; Treatment Outcome | 1998 |
Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coculture Techniques; Cyclopropanes; Drug Synergism; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Interferon-gamma; Interleukin-2; Lamivudine; Lymphocyte Activation; Lymphocyte Subsets; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; Stavudine | 2002 |
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cyclopropanes; Didanosine; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Lamivudine; Male; Organophosphonates; Oxazines; Pulse Therapy, Drug; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome | 2002 |
Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Determining the relative efficacy of highly active antiretroviral therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2003 |
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Oxazines; RNA, Viral; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nelfinavir; Oxazines; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Trizivir vs. efavirenz: results from ACTG 5095.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Placebos; Viral Load; Zidovudine | 2003 |
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2004 |
A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.
Topics: Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; Cholesterol; Cyclopropanes; Didanosine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Polymerase Chain Reaction; RNA, Viral; Triglycerides | 2004 |
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.
Topics: Administration, Oral; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Costs and Cost Analysis; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Outpatient Clinics, Hospital; Oxazines; Pilot Projects; South Africa; Treatment Outcome; Tuberculosis; Urban Population | 2004 |
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Oxazines; Pyridines; RNA, Viral; Zidovudine | 2004 |
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Prospective Studies; Stavudine; Tenofovir; Viral Load | 2004 |
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2004 |
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Viral; Zidovudine | 2004 |
New once-daily HIV combination better tolerated.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Oxazines; Tenofovir; Zidovudine | 2004 |
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2005 |
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Male; Nevirapine; Oxazines; Proportional Hazards Models; RNA, Viral; Stavudine; Treatment Outcome | 2005 |
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine | 2005 |
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Oxazines; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; Quality of Life; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Stavudine; Viral Load | 2005 |
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; RNA, Viral; Zidovudine | 2005 |
An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 1999 |
Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Retrospective Studies; Treatment Outcome; Tunisia; Viremia; Zidovudine | 2005 |
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
Topics: Adiposity; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Oligopeptides; Oxazines; Pyridines; Zidovudine | 2006 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Oxazines; Patient Compliance; Peptide Fragments; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2006 |
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2006 |
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Messenger; Viral Load; Zidovudine | 2006 |
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Treatment Outcome | 2006 |
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Oxazines; Ritonavir; Stavudine; Treatment Outcome | 2006 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Oxazines; RNA, Viral; Tenofovir; Time Factors; Viral Load; Zidovudine | 2006 |
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Extremities; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipid Metabolism; Lipids; Male; Middle Aged; Oxazines; Stavudine; Viral Load | 2007 |
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Body Composition; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Insulin Resistance; Lactic Acid; Lamivudine; Lipids; Male; Reverse Transcriptase Inhibitors; Zidovudine | 2007 |
Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Benzoxazines; Candidiasis, Oral; Cyclopropanes; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Ketoconazole; Lamivudine; Male; Middle Aged; Stavudine | 2007 |
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Prospective Studies; Regression Analysis; RNA, Viral; Time Factors; Zidovudine | 2007 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
A comparison of three initial antiretroviral AIDS regimens.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2007 |
144-week data released on Gilead's study 934.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Time Factors; Viral Load; Zidovudine | 2007 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2008 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication | 2007 |
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
Topics: Adult; Alkynes; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Developing Countries; Dizziness; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; South Africa; Treatment Outcome; Viral Load; Vomiting; Zidovudine | 2008 |
Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Zidovudine | 2008 |
Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2008 |
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
Topics: Adult; Albumins; Alkynes; Anti-HIV Agents; Antioxidants; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Drugs, Generic; Female; Glutathione Peroxidase; Glutathione Reductase; HIV Infections; Humans; India; Lamivudine; Male; Oxidative Stress; Reverse Transcriptase Inhibitors; Stavudine; Uric Acid; Young Adult; Zidovudine | 2008 |
Lack of a significant drug interaction between raltegravir and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Time Factors; Zidovudine | 2008 |
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Thailand; Treatment Outcome; Zidovudine | 2008 |
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Piperazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Didanosine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Prospective Studies; Spain; Treatment Outcome | 2009 |
A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; Humans; Inflammation Mediators; Lamivudine; Lopinavir; Male; Middle Aged; Osteoporosis; Prospective Studies; Pyrimidinones; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Risk Factors; Ritonavir; Zidovudine | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Extremities; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult; Zidovudine | 2009 |
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genome, Viral; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Tenofovir; Treatment Failure; Zidovudine | 2009 |
96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Triazoles; Zidovudine | 2009 |
Raltegravir as effective as efavirenz in 144-week data.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome | 2009 |
[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hyperinsulinism; Hyperlipidemias; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Thymidine; Treatment Outcome; Young Adult | 2009 |
Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Failure; Tuberculosis | 2009 |
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Withholding Treatment | 2010 |
Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cyclopropanes; Drug Therapy, Combination; Fatty Acids; Female; Gene Expression; Genes, Mitochondrial; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation; Zidovudine | 2009 |
The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Culture; Cyclopropanes; Didanosine; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Surveys and Questionnaires; Zidovudine | 2010 |
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Receptors, CCR5; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult; Zidovudine | 2010 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Patient Compliance; Patient Satisfaction; Quality of Life; Reverse Transcriptase Inhibitors; Treatment Outcome; United States; Viral Load | 2010 |
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; beta 2-Microglobulin; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Middle Aged; Organophosphonates; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
Topics: Adolescent; Africa, Western; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Treatment Outcome | 2010 |
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
Topics: Absorptiometry, Photon; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2010 |
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Treatment Outcome; Viral Load; Zidovudine | 2011 |
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Confidence Intervals; Cross-Over Studies; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Uganda | 2010 |
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2011 |
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cholesterol; Cyclopropanes; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Japan; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2011 |
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Quality of Life; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Dexamethasone; Double-Blind Method; Female; HIV Infections; Humans; Lamivudine; Male; Placebos; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Meningeal; Zidovudine | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.
Topics: Acidosis, Lactic; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lactates; Lamivudine; Male; Reverse Transcriptase Inhibitors; South Africa; Stavudine; Treatment Outcome | 2011 |
Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; Viral Load | 2011 |
Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Uganda | 2011 |
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Stavudine | 2011 |
Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.
Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Half-Life; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Viral Load | 2012 |
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black or African American; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Sex Factors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cholesterol, HDL; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Thailand; Triglycerides; Tuberculosis; Young Adult | 2012 |
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; C-Reactive Protein; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV-1; Humans; Inflammation; Interleukin-6; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tumor Necrosis Factor-alpha | 2012 |
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; Gambia; HIV Infections; HIV-1; HIV-2; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Tenofovir | 2012 |
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Female; Genitalia, Female; HIV Infections; Humans; Lamivudine; Models, Biological; Oligopeptides; Organophosphonates; Premenopause; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Blood Glucose; Body Composition; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Linear Models; Lipids; Longitudinal Studies; Male; Organophosphonates; Stavudine; Tenofovir | 2013 |
A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Models, Theoretical; Predictive Value of Tests; Treatment Failure; Viral Load | 2013 |
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; C-Reactive Protein; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Furans; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Middle Aged; Organophosphates; Plasminogen; Prospective Studies; Ritonavir; Sulfonamides; Vascular Cell Adhesion Molecule-1; Young Adult | 2013 |
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone and Bones; Bone Density; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome | 2013 |
A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anthropometry; Anti-HIV Agents; Benzoxazines; Biomarkers; Body Composition; Cyclopropanes; DNA, Mitochondrial; Dose-Response Relationship, Drug; Drug Substitution; Female; Glucose; HIV Infections; Humans; Inflammation; Lamivudine; Lipid Metabolism; Male; Middle Aged; Phosphorous Acids; South Africa; Stavudine | 2014 |
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Benzoxazines; Cambodia; Chromatography, Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; HIV Infections; Humans; Isoniazid; Lamivudine; Plasma; Polymorphism, Single Nucleotide; Rifampin; Spectrophotometry, Ultraviolet; Stavudine; Tuberculosis | 2014 |
24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Confidence Intervals; Cyclopropanes; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; RNA, Viral; Surveys and Questionnaires; Viral Load | 2013 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Brazil; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2014 |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Young Adult; Zidovudine | 2014 |
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Mass Index; C-Reactive Protein; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Selenium; World Health Organization; Zidovudine | 2014 |
A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
Topics: Adult; Alkynes; Benzoxazines; Cholesterol; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Lamivudine; Male; Middle Aged; Tenofovir | 2015 |
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Stavudine; Tablets; Uganda; Zambia; Zidovudine | 2016 |
Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Resorption; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Plasma; Tenofovir; Vitamin D-Binding Protein; Young Adult | 2016 |
Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Amenorrhea; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Desogestrel; Drug Combinations; Drug Implants; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Metrorrhagia; Prospective Studies; Ritonavir; Young Adult; Zidovudine | 2016 |
Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; Colombia; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drugs, Generic; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Treatment Outcome; Viral Load | 2016 |
Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Patient Safety; Pregnancy; Primary Prevention; RNA, Viral; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Viral Load; Zidovudine | 2017 |
Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Insulin-Like Growth Factor I; Lamivudine; Male; Prospective Studies; Tenofovir; Zidovudine | 2017 |
Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Burkina Faso; Child, Preschool; Cote d'Ivoire; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2017 |
Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tablets; Tenofovir; Thailand | 2017 |
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Elasticity Imaging Techniques; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Raltegravir Potassium; Tenofovir; Triglycerides; Waist-Hip Ratio | 2017 |
Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biological Variation, Population; Child; Child, Preschool; Cyclopropanes; Drug Monitoring; Female; HIV Infections; Humans; Lamivudine; Male; Tanzania; Zidovudine | 2018 |
[Effectiveness and safety of generic version of lamivudine/tenofovir and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2012-2014].
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Colombia; Cyclopropanes; Drugs, Generic; Female; Humans; Lamivudine; Male; Prospective Studies; Reproducibility of Results; Statistics, Nonparametric; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2019 |
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Obesity; Oxazines; Piperazines; Pregnancy; Pyridones; RNA, Viral; Tenofovir; Viral Load; Weight Gain | 2019 |
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Outcome Assessment, Health Care; Pregnancy; Pregnancy Complications, Infectious; Raltegravir Potassium; Viral Load; Young Adult; Zidovudine | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Raltegravir Potassium; Vigna; Viral Load; Virus Shedding; Zidovudine | 2021 |
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Oxazines; Piperazines; Postpartum Period; Pregnancy; Pyridones; Tenofovir; Viral Load | 2022 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Topics: Adult; Anti-Retroviral Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; RNA; Tenofovir | 2023 |
Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Tenofovir; Treatment Outcome; Viral Load | 2023 |
254 other study(ies) available for lamivudine and efavirenz
| Article | Year |
|---|---|
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Cell Line; Dogs; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Inhibitors | 2007 |
Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
Topics: Antiviral Agents; Cell Line; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans | 2008 |
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
Topics: Anti-HIV Agents; Catalytic Domain; CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Synergism; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Molecular Structure; Mutation; Protein Structure, Tertiary; Recombinant Proteins; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; T-Lymphocytes | 2009 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Nitriles; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
Topics: Anti-HIV Agents; Cell Line; Cell Line, Transformed; Drug Resistance, Viral; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Naphthyridines; T-Lymphocytes; Virus Integration; Virus Replication | 2011 |
Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Daphne; Diterpenes; Heterocyclic Compounds, 4 or More Rings; Mediterranean Region; Molecular Structure; Receptors, CXCR4 | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Benzamides; Cell Survival; Cells, Cultured; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Replication | 2014 |
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Microbial Sensitivity Tests; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Niacinamide; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Nitrogen; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Sulfones | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
Topics: Anti-HIV Agents; Chemistry Techniques, Synthetic; Computational Biology; Drug Design; HIV Reverse Transcriptase; HIV-1; Imidazoles; Molecular Docking Simulation; Protein Conformation; Pyrazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
Topics: Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; Molecular Docking Simulation; Protein Conformation; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Water | 2016 |
Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
Topics: Animals; Anti-HIV Agents; Cell Line, Tumor; Drug Resistance, Viral; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Molecular Docking Simulation; Mutation; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfonamides; Thiophenes | 2016 |
Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities.
Topics: 4-Butyrolactone; Anti-HIV Agents; Aspergillus; China; Cytochalasins; Diterpenes; Endophytes; Inhibitory Concentration 50; Kadsura; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Phenalenes | 2017 |
Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Humans; Indazoles; Microbial Sensitivity Tests; Molecular Structure; Piperidines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2020 |
Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Morpholines; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Water | 2020 |
Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV-1; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Naphthalenes; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Evaluation; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viremia; Zidovudine | 1998 |
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |
Efavirenz in HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Oxazines; Research Design; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2000 |
Efavirenz decreases methadone blood concentrations.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Methadone; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Substance Withdrawal Syndrome | 2000 |
Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Didanosine; Environmental Monitoring; HIV Infections; HIV-1; Humans; Hydroxyurea; Lamivudine; Male; Oxazines; Semen; Time Factors; Viral Load | 2001 |
Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cell Line; Cyclopropanes; Didanosine; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Core Protein p24; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Catalytic; T-Lymphocytes; Time Factors | 2001 |
Dethroning AZT.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; Oxazines; Stavudine; Viral Load; Zidovudine | 1997 |
New drugs on the horizon.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States; Zidovudine | 1998 |
First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Lamivudine; Lipodystrophy; Oxazines; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1998 |
A new HAART on the horizon says the proof is in the potency.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Oxazines; Patient Compliance; Pregnancy; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
New study shows efavirenz effective with d4T and 3TC.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cerebrospinal Fluid; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Vagina; Viral Load; Zidovudine | 1999 |
Antiretroviral rounds. When success is a pain.
Topics: Abdominal Pain; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2001 |
A case of lipodystrophy after the initiation of zidovudine, lamivudine and efavirenz in an asymptomatic HIV-1-infected patient.
Topics: Abdomen; Adipose Tissue; Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Lipodystrophy; Male; Oxazines; Reverse Transcriptase Inhibitors; Tomography, X-Ray Computed; Zidovudine | 2000 |
Antiretroviral rounds. A very discordant response.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Practice Patterns, Physicians'; Reverse Transcriptase Inhibitors; Stavudine; Viral Load | 2002 |
Myelomeningocele in a child with intrauterine exposure to efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Lamivudine; Male; Maternal Exposure; Meningomyelocele; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Reverse Transcriptase Inhibitors; Stavudine | 2002 |
Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Sarcoma, Kaposi; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Clinical trials group: two studies are now open to patients who qualify.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Oxazines; Patient Selection; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Zidovudine | 2000 |
Efavirenz-induced leukocytoclastic vasculitis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biopsy, Needle; Cyclopropanes; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Oxazines; Prednisone; Risk Assessment; Severity of Illness Index; Skin; Stavudine; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2002 |
Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Eruptions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Spouses; Stavudine; Time Factors | 2001 |
Immune reconstitution eosinophilia due to schistosomiasis.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Eosinophilia; Female; Humans; Lamivudine; Oxazines; Schistosomiasis; Stavudine | 2002 |
Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Prospective Studies; RNA, Viral | 2001 |
Normalization of liver enzymes in an HIV-hepatitis C virus-co-infected patient after potent antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Lamivudine; Liver; Oxazines; RNA, Viral; Zidovudine | 2002 |
HIV and refractory anemia with excess blasts (RAEB).
Topics: Adult; Alkynes; Anemia, Refractory, with Excess of Blasts; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Lamivudine; Male; Oxazines; Pancytopenia; Pneumonia; Stavudine; Treatment Outcome | 2002 |
Determination of lamivudine/stavudine/efavirenz in human serum using liquid chromatography/electrospray tandem mass spectrometry with ionization polarity switch.
Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Humans; Lamivudine; Oxazines; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Stavudine | 2002 |
Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genes, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Oxazines; RNA, Viral; Stavudine; Viral Load; Viremia | 2002 |
Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Uganda; Viral Load; Zidovudine | 2002 |
Chronic cough induced by abacavir apart from a context of hypersensitivity.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chronic Disease; Cough; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Middle Aged; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Rhinitis; Sputum; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination | 2002 |
AIDS drug in halted trial less effective as monotherapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2003 |
[Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Viremia; Zidovudine | 2003 |
Triple combinations regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Oxazines; Randomized Controlled Trials as Topic; Tenofovir; Treatment Failure | 2003 |
Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-CD8 Ratio; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Flow Cytometry; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Activation; Lymphocyte Subsets; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2004 |
[Ensuring high adherence. Clever combination assures therapeutic success].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Oxazines; Patient Compliance; Randomized Controlled Trials as Topic; Treatment Outcome; Zidovudine | 2003 |
[Lipid profile and body fat--significant "side effect" of antiretroviral therapy. Tenofovir: favorable profile of adverse effects].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Humans; Lamivudine; Lipids; Organophosphonates; Organophosphorus Compounds; Oxazines; Stavudine; Tenofovir | 2003 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Research Design; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2004 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
[3 years' data of tenofovir. Confirmed as a valuable building block].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; Humans; Lamivudine; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
[Valuable combination partner. Great benefit for therapy naive patients].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Multicenter Studies as Topic; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2005 |
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Oxazines; RNA, Viral; Stavudine; Tenofovir; Viremia | 2005 |
Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drugs, Generic; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Middle Aged; Oxazines; Prospective Studies; Tablets; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Recurrence of post-traumatic stress disorder and antiretrovirals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Recurrence; RNA, Viral; Stress Disorders, Post-Traumatic; Viral Load; Zidovudine | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Brazil; Cervix Uteri; Cross-Sectional Studies; Cyclopropanes; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Nelfinavir; Prevalence; Time Factors; Vagina; Viral Load; Zidovudine | 2006 |
Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Calibration; Cyclopropanes; Dose-Response Relationship, Drug; Drug Monitoring; Gas Chromatography-Mass Spectrometry; HIV Infections; Humans; Ions; Lamivudine; Molecular Structure; Nevirapine; Oxazines; Reproducibility of Results | 2005 |
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Antiretroviral treatment in the Northern Cape.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Nevirapine; Oxazines; Pyrimidinones; Ritonavir; South Africa; Stavudine; Viral Load | 2005 |
HIV-1 reverse transcriptase gene 103K/N and 184M/V combinations in tandem: detection and quantification of HIV-1 populations in the CD45RO+ T-cell compartment by a double-ARMS real-time PCR assay.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Genes, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Immunologic Memory; Lamivudine; Leukocyte Common Antigens; Male; Middle Aged; Mutation; Nevirapine; Oxazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; T-Lymphocytes; Viral Load | 2006 |
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Oxazines; Patient Compliance; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; RNA, Viral; ROC Curve; Stavudine | 2006 |
A case of voluntary intoxication with efavirenz and lamivudine.
Topics: Adolescent; Alkynes; Benzoxazines; Cyclopropanes; Female; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Self-Injurious Behavior; Suicide, Attempted | 2006 |
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Lipoproteins; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Triglycerides | 2006 |
Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Controlled Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Oxazines; Prospective Studies; Time Factors; Treatment Outcome; Zidovudine | 2006 |
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Oxazines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary; Viral Load | 2006 |
[Effects of traditional Chinese medicine on CD4 + T cell counts and HIV viral loads during structured treatment interruption in highly active antiretroviral therapy].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Phytotherapy; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2006 |
Visual loss secondary to acquired immunodeficiency virus-related progressive multifocal leukoencephalopathy demonstrating clinical improvement with highly active antiretroviral therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Drug Therapy, Combination; Hemianopsia; Humans; JC Virus; Lamivudine; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Organophosphonates; Oxazines; Tenofovir; Tomography, X-Ray Computed; Vision Disorders; Visual Fields | 2007 |
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Hypersensitivity; HIV Infections; Humans; Lamivudine; Male; Oxazines; RNA, Viral | 2007 |
Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Exanthema; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Nevirapine; Pancreatitis; Peripheral Nervous System Diseases; Proportional Hazards Models; Rural Health; Stavudine; Survival Analysis; Uganda | 2007 |
Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child Development; Child, Preschool; Cholesterol; Cohort Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Oxazines; Patient Compliance; Prospective Studies; Treatment Outcome | 2007 |
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocyte Common Antigens; Mutation; Nevirapine; Nucleic Acid Amplification Techniques; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; T-Lymphocytes; Viremia | 2007 |
Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Cohort Studies; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Retrospective Studies; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2007 |
Hair loss induced by lopinavir-ritonavir.
Topics: Adult; Alkynes; Alopecia; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Probability; Pyrimidinones; Ritonavir | 2007 |
Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: In vivo and in vitro findings.
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Chemokine CCL2; Cyclopropanes; Drug Resistance, Viral; Flow Cytometry; Gene Expression; HIV Infections; HIV-1; Humans; In Vitro Techniques; Interleukin-8; Lamivudine; Male; Prednisolone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Uveitis; Viral Load; Viremia; Zidovudine | 2007 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Spain; Species Specificity; Treatment Failure; Viral Load | 2007 |
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Administration Schedule; Female; Food; HIV; HIV Infections; Humans; Lamivudine; Male; Spain; Viral Load | 2007 |
Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Aspartate Aminotransferases; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Linear Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Stavudine; Zidovudine | 2007 |
Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Feasibility Studies; Female; HIV Infections; HIV-1; Humans; Lamivudine; Logistic Models; Male; Prospective Studies; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2007 |
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hyperglycemia; Hypertriglyceridemia; Lamivudine; Lipodystrophy; Male; Nevirapine; Prevalence; Reverse Transcriptase Inhibitors; Stavudine; Thailand | 2007 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Deoxycytidine; Drug Costs; Emtricitabine; Health Care Costs; Health Resources; HIV Infections; HIV-1; Humans; Lamivudine; Models, Economic; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Zidovudine | 2008 |
[Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkina Faso; CD4 Lymphocyte Count; Cyclopropanes; Female; Follow-Up Studies; Foot Diseases; HIV Infections; Humans; Hypesthesia; Lamivudine; Male; Middle Aged; Nevirapine; Pain; Paresthesia; Polyneuropathies; Reflex, Abnormal; Sensory Thresholds; Stavudine; Vibration | 2008 |
[Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Congo; Cyclopropanes; Didanosine; Drug Evaluation; Drug Therapy, Combination; Female; Hematology; HIV Infections; Hospital Departments; Hospitals, University; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2008 |
A case of human bite by an 11-year old HIV positive girl in a paediatrics ward.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Bites, Human; Child; Cyclopropanes; Female; HIV Infections; Humans; Inpatients; Lamivudine; Male; Zidovudine | 2008 |
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Topics: Adenine; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Mutation, Missense; Nevirapine; Organophosphonates; Plasma; Polymerase Chain Reaction; Selection, Genetic; Tenofovir; Treatment Failure | 2009 |
A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; India; Lamivudine; Male; Medication Adherence; Nevirapine; Prospective Studies; Stavudine; Treatment Outcome; Zidovudine | 2009 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients.
Topics: Adenine; Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Ribonuclease H, Human Immunodeficiency Virus; Stavudine; Tenofovir | 2009 |
Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Thymidine; Treatment Failure; Uganda | 2009 |
[Tolerance study of a triple first-line antiretroviral combination zidovudine, lamivudine and efavirenz in Dakar, Senegal].
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anemia; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Drug Tolerance; HIV-1; Humans; Lamivudine; Senegal; Zidovudine | 2009 |
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; HIV Infections; Humans; Immunization; Lamivudine; Longitudinal Studies; Male; Middle Aged; Mycobacterium tuberculosis; Nevirapine; Stavudine; T-Lymphocytes; Tuberculosis | 2009 |
Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cultural Competency; Cyclohexanes; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Language; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results; Stress, Psychological; Surveys and Questionnaires; Triazoles; Zidovudine | 2009 |
FDA notifications. FDA approves generic combination of efavirenz, lamivudine & tenofovir.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Approval; Drug Combinations; Drugs, Generic; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Polymerase Chain Reaction; Zidovudine | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
Elvucitabine data released at CROI.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zalcitabine | 2010 |
Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Lamivudine; Molecular Sequence Data; Nevirapine; Polymorphism, Single Nucleotide; Stavudine; Treatment Failure; Zidovudine | 2010 |
Breast enlargement in an HIV-infected man on combined antiretroviral therapy: what if it was carcinoma?
Topics: Alkynes; Benzoxazines; Breast Neoplasms, Male; Carcinoma, Intraductal, Noninfiltrating; Cyclopropanes; Didanosine; Drug Therapy, Combination; Gynecomastia; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Randomized Controlled Trials as Topic; Tenofovir | 2010 |
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d'Ivoire; Cyclopropanes; Drug Therapy, Combination; Enterobacter aerogenes; Enterobacteriaceae Infections; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Malaria; Male; Middle Aged; Organophosphonates; Pyelonephritis; Pyrimidinones; Ritonavir; Tenofovir | 2011 |
Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Multivariate Analysis; Nevirapine; Prospective Studies; Risk Factors; Sex Factors; Stavudine; Uganda; Zidovudine | 2011 |
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Lamivudine; Male; Middle Aged; Nevirapine; RNA, Viral; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2010 |
Aminotransferase serum levels decrease after initiating antiretroviral treatment in HIV infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Pyrimidinones; Ritonavir; Serum; Transaminases; Zidovudine | 2011 |
[Comparative study of two anti-antiretroviral protocols used for treatment of a cohort of HIV 1-positive patients followed at the Institute of Public Health and Hygiene in Dakar, Senegal].
Topics: Academies and Institutes; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Seropositivity; HIV-1; Humans; Hygiene; Lamivudine; Nevirapine; Public Health; Quality of Life; Retrospective Studies; Senegal; Survival Analysis; Treatment Outcome; Zidovudine | 2011 |
Battles with donors cloud Malawi's HIV prevention plan.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Charities; Cyclopropanes; Drug Costs; Drug Therapy, Combination; Female; Health Policy; HIV Seropositivity; Humans; Infectious Disease Transmission, Vertical; International Cooperation; Lamivudine; Malawi; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2011 |
Multiple sclerosis typical clinical and MRI findings in a patient with HIV infection.
Topics: Adult; Age of Onset; Alkynes; Benzoxazines; Brain; CD4 Lymphocyte Count; Cyclopropanes; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Neuroimaging; Stavudine; Treatment Outcome; Viral Load | 2011 |
HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India.
Topics: Alkynes; Anemia; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Exanthema; Female; Gastritis; HIV Infections; Humans; India; Lamivudine; Male; Nevirapine; Peripheral Nervous System Diseases; Pharmacovigilance; Retrospective Studies; Severity of Illness Index; Sjogren's Syndrome; Stavudine | 2011 |
Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Dominican Republic; Drug Administration Schedule; Drug Costs; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Zidovudine | 2012 |
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; South Africa; Stavudine; Viral Load | 2012 |
Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients.
Topics: Adolescent; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Oxidoreductases, N-Demethylating; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; South Africa; Stavudine; Viral Load; Young Adult | 2012 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Organophosphonates; Pain; Retrospective Studies; Risk Factors; Stavudine; Tenofovir; Zidovudine | 2012 |
Immunological characterisation of an unmasking TB-IRIS case.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytokines; Female; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Male; Opportunistic Infections; Stavudine; Thymic Factor, Circulating; Tuberculosis, Pulmonary | 2012 |
Response to valacyclovir in an HIV-infected girl with Epstein Barr infection.
Topics: Acyclovir; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Child; Cyclopropanes; Epstein-Barr Virus Infections; Female; HIV Infections; Humans; Lamivudine; Valacyclovir; Valine; Zidovudine | 2012 |
Monitoring of HAART regime antiretrovirals in serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Humans; Lamivudine; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Retrospective Studies; Risk Factors; South Africa; Stavudine; Time Factors | 2013 |
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Nevirapine; Nigeria; Organophosphorus Compounds; RNA, Viral; Stavudine; Zidovudine | 2013 |
[A case of vitiligo occurring after initiation of antiretroviral treatment and disappearing during this treatment: autoimmune IRIS syndrome?].
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Follow-Up Studies; HIV Seropositivity; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Male; Viral Load; Vitiligo; Zidovudine | 2012 |
[Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Senegal; Tenofovir; Treatment Outcome | 2013 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Ethambutol; Female; Genotype; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Middle Aged; Organophosphonates; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Tenofovir; Tuberculosis; Young Adult | 2013 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity; Drug Substitution; Emtricitabine; Female; Fever; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Syndrome; Tenofovir | 2013 |
Comparison of supercritical fluid chromatography and reverse phase liquid chromatography for the impurity profiling of the antiretroviral drugs lamivudine/BMS-986001/efavirenz in a combination tablet.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, Liquid; Chromatography, Supercritical Fluid; Cyclopropanes; Drug Combinations; Hydrogen-Ion Concentration; Lamivudine; Reverse Transcriptase Inhibitors; Tablets; Temperature; Thymidine | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors; United States | 2013 |
Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Health Services; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Models, Econometric; Mothers; Nevirapine; Pregnancy; Thailand; Zidovudine | 2015 |
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Lamivudine; Male; Medication Adherence; Nevirapine; Risk Factors; South Africa; Stavudine; Time Factors; Tuberculosis; Viral Load | 2013 |
Hepatitis B prevalence and influence on HIV treatment outcome and mortality in the Chilean AIDS Cohort.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Chile; Coinfection; Cyclopropanes; Female; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Prevalence; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2013 |
Regression of oral Kaposi's sarcoma after combination antiretroviral therapy.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Humans; Lamivudine; Male; Organophosphonates; Sarcoma, Kaposi; Tenofovir | 2013 |
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load | 2013 |
HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Resistance, Viral; Epidemiological Monitoring; Female; Ghana; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Lamivudine; Male; Middle Aged; Molecular Epidemiology; Molecular Typing; Mutation, Missense; Nevirapine; Prevalence; Sequence Analysis, DNA; Stavudine; Zidovudine | 2013 |
High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
Topics: Adolescent; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Nevirapine; Outcome Assessment, Health Care; Prevalence; South Africa; Stavudine; Young Adult; Zidovudine | 2013 |
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2014 |
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Asian People; Benzoxazines; Biomarkers; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; Gene Frequency; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Polymorphism, Single Nucleotide; Prospective Studies; Tenofovir; Young Adult | 2014 |
Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
Topics: Adult; Alkynes; Area Under Curve; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Pharmacogenetics; Reverse Transcriptase Inhibitors; Treatment Outcome; Uganda; Zidovudine | 2014 |
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Liver; Logistic Models; Male; Middle Aged; Nevirapine; Proportional Hazards Models; Retrospective Studies; Stavudine; Treatment Outcome; Zidovudine | 2014 |
Challenges of antiretroviral treatment monitoring in rural and remote-access regions in Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Africa; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Female; HIV-1; Hospitals, Rural; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Rural Health Services; Rural Population; Stavudine; Treatment Outcome; Zidovudine | 2014 |
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemoprevention; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Retrospective Studies; Rural Population; Tenofovir; Young Adult | 2014 |
Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dried Blood Spot Testing; Drug Resistance, Viral; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Papua New Guinea; Reverse Transcriptase Inhibitors; Stavudine; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2014 |
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
Topics: Alkynes; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Benzoxazines; Cell Line; Cognition Disorders; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Mice; Oxidative Stress; Phagocytosis; Reverse Transcriptase Inhibitors; Zidovudine | 2014 |
ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Creatinine; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Drug Resistance, Viral; Female; Gene Expression Regulation; HIV; Humans; Lamivudine; Leukocytes, Mononuclear; Male; MicroRNAs; Nevirapine; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Nevirapine; Organophosphonates; Pyrimidines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2014 |
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
Topics: Adenine; Adult; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Interleukin-10; Interleukin-6; Interleukin-8; Lamivudine; Male; Middle Aged; Organophosphonates; Platelet Activating Factor; Tenofovir; Tumor Necrosis Factor-alpha | 2014 |
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
Topics: Alkynes; Benzoxazines; China; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2014 |
In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.
Topics: Alkynes; Benzoxazines; Cells, Cultured; China; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Molecular Sequence Data; Mutant Proteins; Mutation, Missense; Nevirapine; Reverse Transcriptase Inhibitors; Selection, Genetic; Sequence Analysis, DNA; Virus Cultivation | 2015 |
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Cognition Disorders; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Prospective Studies; Tenofovir; Tumor Necrosis Factor-alpha; Viral Load | 2015 |
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Calcium; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Urinalysis; Viral Load | 2015 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2015 |
[Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Health Facilities; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Stavudine; Time-to-Treatment; Treatment Outcome; Zidovudine | 2015 |
Time trends of baseline demographics and clinical characteristics of HIV infected children enrolled in care and treatment service in Dar es Salaam, Tanzania.
Topics: Adolescent; Age Distribution; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Comorbidity; Cyclopropanes; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Male; Nevirapine; Severity of Illness Index; Tanzania; Tuberculosis; Zidovudine | 2015 |
Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Estonia; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Zidovudine | 2016 |
Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; India; Lamivudine; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2016 |
COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Government; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Cyclopropanes; Dideoxynucleosides; Drug Combinations; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Lamivudine; Male; Middle Aged; P-Selectin; Tenofovir; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tandem Mass Spectrometry; Tenofovir; Viral Load; Young Adult | 2016 |
Treatment with adalimumab for severe immune reconstitution inflammatory syndrome in an HIV-infected patient presenting with cryptococcal meningitis.
Topics: Adalimumab; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cameroon; Combined Modality Therapy; Cyclopropanes; Delayed Diagnosis; Drug Therapy, Combination; Female; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Meningitis, Cryptococcal; Prednisone; Stavudine; Tumor Necrosis Factor-alpha; Ventriculoperitoneal Shunt | 2016 |
Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; CD4-Positive T-Lymphocytes; Coinfection; Cyclopropanes; Female; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Tenofovir | 2016 |
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Global Health; HIV Infections; HIV-1; Humans; Lamivudine; Pre-Exposure Prophylaxis; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2016 |
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis; Viral Load; Zidovudine | 2016 |
Theoretical and experimental studies of the stability of drug-drug interact.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Stability; Hydrogen Bonding; Lamivudine; Molecular Docking Simulation; Molecular Dynamics Simulation; Thermodynamics; Zidovudine | 2016 |
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Ethiopia; Female; Genetic Variation; Genome, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Immune Evasion; Lamivudine; Male; Mutation; Stavudine; Viral Load; Zidovudine | 2017 |
Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.
Topics: Adult; Alkaline Phosphatase; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Bone Resorption; Breast Feeding; Collagen Type I; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Male; Peptides; Pregnancy; Tenofovir; Young Adult | 2016 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
Interchangeability between first-line generic antiretroviral products prequalified by WHO using adjusted indirect comparisons.
Topics: Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Biological Availability; Cyclopropanes; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Lamivudine; Models, Statistical; Tenofovir; Therapeutic Equivalency; World Health Organization | 2017 |
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Attitude to Health; Benzoxazines; Caregivers; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Nevirapine; Randomized Controlled Trials as Topic; Stavudine; Surveys and Questionnaires; Uganda; Zambia; Zidovudine | 2017 |
Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Disclosure; Female; HIV Infections; HIV Seropositivity; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Nevirapine; Retrospective Studies; Tenofovir; Treatment Outcome; Uganda | 2016 |
Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Models, Theoretical; Young Adult | 2017 |
Survival Outcomes in a Pediatric Antiretroviral Treatment Cohort in Southern Malawi.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleotides; Female; HIV Infections; HIV Wasting Syndrome; Humans; Infant; Lamivudine; Malawi; Male; Proportional Hazards Models; Retrospective Studies; Rural Population; Stavudine; Survival Analysis; Tuberculosis, Pulmonary; Zidovudine | 2016 |
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
Topics: Adult; Africa South of the Sahara; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2017 |
Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Benzoxazines; Cell Line, Tumor; Cyclopropanes; Drug Combinations; Female; Half-Life; HIV Infections; HIV-1; Humans; Lactoferrin; Lamivudine; Male; Nanoparticles; Rats; Rats, Wistar; Tissue Distribution; Zidovudine | 2017 |
Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Hospitals; Humans; Lamivudine; Lipodystrophy; Male; Middle Aged; Retrospective Studies; Rural Population; South Africa; Stavudine; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load; Young Adult | 2016 |
Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Ataxia; Benzoxazines; Brain Diseases; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; South Africa; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Lamivudine; Male; Models, Theoretical; Nevirapine; Pregnancy; Retrospective Studies; Stavudine; Tenofovir; Time-to-Treatment; Treatment Failure; Zidovudine | 2017 |
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV-1; Lamivudine; Lopinavir; Nelfinavir; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 2017 |
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Patient Safety; Poisson Distribution; RNA, Viral; Treatment Outcome; Zidovudine | 2017 |
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Mozambique; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2017 |
Bullseye Retinopathy from Antiretroviral Therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Humans; Lamivudine; Male; Middle Aged; Retinal Diseases; Reverse Transcriptase Inhibitors; Zidovudine | 2017 |
Human immunodeficiency virus infection acquired through a traditional healer's ritual: a case report.
Topics: Adult; Alkynes; Antiviral Agents; Benzoxazines; Ceremonial Behavior; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Lamivudine; Medicine, Traditional; Tanzania; Tenofovir | 2017 |
Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Immunity, Cellular; Iran; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Sex Factors; Time Factors; Zidovudine | 2018 |
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nausea; Nevirapine; Nigeria; Prospective Studies; Sleep Initiation and Maintenance Disorders; Tenofovir; Young Adult; Zidovudine | 2016 |
Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Prospective Studies; RNA, Viral; Time; Uganda; Viral Load; Zidovudine | 2018 |
Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Infant, Premature; Infant, Small for Gestational Age; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Rural Population; South Africa; Tenofovir; Young Adult | 2018 |
Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drugs, Generic; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Tablets; Viral Load; Zidovudine | 2018 |
Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cross-Sectional Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quality of Life; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2018 |
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Viremia | 2018 |
HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Topics: Adult; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; Health Resources; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Medication Adherence; Ritonavir; South Africa; Viral Load | 2018 |
Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate).
Topics: Alkynes; Animals; Area Under Curve; Benzoxazines; Cimetidine; Cyclopropanes; Dogs; Half-Life; HEK293 Cells; Humans; Kidney; Lamivudine; Madin Darby Canine Kidney Cells; Male; Metformin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Cation Transport Proteins; Rats; Rats, Wistar; Renal Elimination; Reverse Transcriptase Inhibitors; ROC Curve | 2018 |
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Gynecomastia; HIV Infections; Humans; Lamivudine; Male; Mucositis; Nevirapine; Reverse Transcriptase Inhibitors; Stevens-Johnson Syndrome | 2018 |
Symfi, Symfi Lo, and Cimduo for HIV.
Topics: Adenine; Administration, Oral; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Interactions; HIV Infections; HIV-1; Humans; Lamivudine; Phosphorous Acids; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2019 |
Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cameroon; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nevirapine; Patient Compliance; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2019 |
Option B plus antiretroviral therapy adherence and associated factors among HIV positive pregnant women in Southern Ethiopia.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Directive Counseling; Drug Therapy, Combination; Ethiopia; Female; Health Services Accessibility; HIV Seropositivity; Hospitals, Public; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Medication Adherence; Pregnancy; Prenatal Care; Surveys and Questionnaires; Tenofovir; Time Factors; Travel; Young Adult | 2019 |
Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Sustained Virologic Response; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2019 |
Reply to Lanzafame et al.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Emtricitabine; HIV-1; Humans; Lamivudine; Tenofovir | 2019 |
DRIVE-AHEAD Trial's Results and the Need for a More Appropriate Comparator Drug.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Emtricitabine; HIV-1; Humans; Lamivudine; Tenofovir | 2019 |
Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Middle Aged; Mutation; Nevirapine; Stavudine; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis.
Topics: Alkynes; Benzoxazines; Brain; Creatinine; Cyclopropanes; Humans; Lamivudine; Meningitis, Cryptococcal; Postmortem Changes; Tenofovir | 2019 |
Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2019 |
Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Topics: Adolescent; Adult; Age Factors; Albuminuria; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Sex Factors; Tenofovir; Young Adult; Zidovudine | 2020 |
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Prevalence; Reverse Transcriptase Inhibitors; Taiwan; Zidovudine | 2019 |
Severe hepatotoxicity induced by efavirenz in a treatment-naïve, low body mass index HIV-infected, female patient with no hepatitis and other virus co-infections.
Topics: Adult; Alkynes; Benzoxazines; Body Mass Index; Chemical and Drug Induced Liver Injury; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2019 |
HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Microcephaly; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Puerto Rico; Tenofovir; Young Adult; Zidovudine | 2020 |
'High' antiretroviral deintensification strategy and cellular HIV DNA levels.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; Pilot Projects | 2020 |
Traditional Chinese Medicine Can Improve the Immune Reconstruction of HIV/AIDS Patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Drugs, Chinese Herbal; HIV Infections; Humans; Immune Reconstitution; Lamivudine; Medicine, Chinese Traditional; Middle Aged; Pilot Projects; Prospective Studies; T-Lymphocytes; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal; Benzoxazines; Child; Cryptococcus neoformans; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fluconazole; HIV; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Lopinavir; Meningitis, Cryptococcal; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2020 |
Diagnosis of elephantiasis nostras verrucosa as a clinical mani-festation of Kaposi's sarcoma.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; Elephantiasis; Humans; Lamivudine; Male; Middle Aged; Sarcoma, Kaposi | 2020 |
Influence of a herbal preparation on the pharmacokinetics of highly active antiretroviral therapy drugs in rats.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Herb-Drug Interactions; Lamivudine; Male; Rats; Zidovudine | 2020 |
Movement disorder in a patient with Human Immunodeficiency Virus on an anti-retroviral therapy: A Case Report.
Topics: AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Brain Barrier; Brain Stem; Cerebellar Ataxia; Cerebellum; Cyclopropanes; Drug Substitution; Female; Gait Ataxia; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Neurodegenerative Diseases; Nystagmus, Pathologic; Panic Disorder; Pons; Postural Balance; Sensation Disorders; Tenofovir; Zidovudine | 2020 |
The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty.
Topics: Adult; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkitt Lymphoma; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cementoplasty; Cyclophosphamide; Cyclopropanes; Doxorubicin; Female; Fractures, Compression; HIV Infections; Humans; Kyphoplasty; Lamivudine; Lumbar Vertebrae; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Spinal Fractures; Tenofovir; Tomography, X-Ray Computed; Vincristine; Viral Load | 2020 |
Modeling cerebellar limb dysmetria and impaired spatial memory in rats using lamivudine: A preliminary study.
Topics: Alkynes; Animals; Benzoxazines; Cerebellar Ataxia; Cyclopropanes; Disease Models, Animal; Lamivudine; Male; Maze Learning; Rats; Rats, Wistar; Spatial Memory; Tenofovir | 2020 |
Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; Humans; Hypercalcemia; Hyperkalemia; Hyperphosphatemia; Hypocalcemia; Hypokalemia; Hypophosphatemia; Lamivudine; Male; Middle Aged; Prevalence; Proteinuria; Renal Insufficiency; Tenofovir; Uganda | 2020 |
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral sup
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Substitution; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Taiwan; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa.
Topics: Administration, Oral; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Epidemics; Female; HIV Seropositivity; HIV-1; Humans; Lamivudine; Pre-Exposure Prophylaxis; Retrospective Studies; South Africa; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2020 |
Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Betacoronavirus; C-Reactive Protein; CD4 Lymphocyte Count; Chills; Coronavirus Infections; COVID-19; Cyclopropanes; Fatigue; Female; Fever; HIV; HIV Infections; Humans; Immunocompromised Host; Immunoglobulin M; Lamivudine; Middle Aged; Pandemics; Pharyngitis; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; SARS-CoV-2; Sputum; Time Factors; Tomography, X-Ray Computed; Virus Shedding; Zidovudine | 2020 |
Assessing the association between platelets and immune recovery in HIV/HBV co-infected patients: A long-term cohort in Asia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Platelets; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immune Reconstitution; Lamivudine; Longitudinal Studies; Male; Platelet Count; Retrospective Studies; Tenofovir | 2020 |
Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibito
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Middle Aged; Private Sector; Retrospective Studies; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2020 |
Lamivudine-conjugated and efavirenz-loaded G2 dendrimers: Novel anti-retroviral nano drug delivery systems.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dendrimers; Drug Delivery Systems; HEK293 Cells; Humans; Lamivudine | 2021 |
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Tenofovir | 2022 |
Levels of adherence to contemporary antiretroviral regimens and the likelihood of viral suppression: a cohort study in a Brazilian metropolis.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Brazil; Cohort Studies; HIV Infections; Humans; Lamivudine; Prospective Studies; Tenofovir | 2023 |
Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Lesotho; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Prospective Studies; Self Report; Tenofovir | 2023 |
Do anti-HIV drugs pose a threat to photosynthetic microorganisms?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Lamivudine; Photosynthesis; Tenofovir; Water | 2022 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
A post-mortem analysis of tenofovir, lamivudine, efavirenz and fluconazole penetration in female genital tissues.
Topics: Anti-HIV Agents; Autopsy; Benzoxazines; Chromatography, Liquid; Female; Fluconazole; Genitalia, Female; HIV Infections; Humans; Lamivudine; Tandem Mass Spectrometry; Tenofovir | 2022 |
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Creatinine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Prospective Studies; Pyridones; RNA; Tenofovir; Triglycerides | 2022 |
Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Cameroon; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load | 2022 |
Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; HIV Infections; HIV-1; Humans; Hypertriglyceridemia; Incidence; Lamivudine; Male; Retrospective Studies; Risk Factors; Tenofovir; Triglycerides | 2023 |
Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
Topics: Adult; Anti-HIV Agents; Bone Density; Cancellous Bone; East Asian People; HIV Infections; Humans; Lamivudine; Male; Muscles; Osteoporosis; Retrospective Studies; Sarcopenia; Stavudine; Tenofovir; Young Adult | 2023 |
Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
Topics: China; Drug Combinations; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Tenofovir | 2023 |
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir.
Topics: Anti-HIV Agents; Benzoxazines; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.
Topics: Adsorption; Ammonium Hydroxide; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Chromatography, Liquid; Emtricitabine; HIV Infections; Humans; Lamivudine; Methanol; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Water | 2023 |
Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Hormonal Contraception; Humans; Lamivudine; Levonorgestrel; Malawi; Medroxyprogesterone Acetate; Microbiota; Tenofovir; Vagina | 2023 |
Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting.
Topics: Child; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Risk Factors; Seroepidemiologic Studies; Tenofovir | 2023 |
Cost-effectiveness analysis of antiretroviral drugs for treatment-naive HIV infection in China.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cost-Effectiveness Analysis; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Lamivudine | 2023 |
Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication | 2016 |
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
Topics: Animals; Antiviral Agents; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; HIV-1; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Uracil | 2016 |
Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Molecular Structure; Mutation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |